



The contribution of 5-HT1A receptors in improving
plasticity and function of the brain
Citation for published version (APA):
Pazinatto Aguiar, R. (2020). The contribution of 5-HT1A receptors in improving plasticity and function of
the brain. Maastricht University. https://doi.org/10.26481/dis.20201215rp





Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
















































Cover design by Gabriel Cruz 
Typesetting and lay-out by Rafael Pazinatto Aguiar 
 
Copyright ©2020 Rafael Pazinatto Aguiar 
 
All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means, 
electronic or mechanical, including photocopying, recording or any information storage or retrieval system, 









THE CONTRIBUTION OF 5-HT1A RECEPTORS IN 





To obtain the degree of Doctor at Maastricht University 
On the authority of the Rector Magnificus 
Prof. Dr. Rianne Monique Letschert 
In accordance with the decision of the Board of Deans  
To be defended in public 















Prof. Dr. J. Prickaerts 
Co-promotor: 
Dr. R.M.M.W. de Oliveira 
 
Evaluation committee: 
Prof. Dr. A. Blokland (Chairman) 
Prof. Dr. D. van den Hove 
Prof. Dr. J. Homberg 
Dr. R. Schreiber 
























5-HT   5-hydroxytryptamine;  
 
CNS   Central nervous system; 
 
DRN   Dorsal raphe nucleus;  
 
MRN   Median raphe nucleus; 
 
CRN   Caudal raphe nucleus; 
 
PFC   Prefrontal cortex;  
 
SERT   Serotonin transporter;  
 
MAO   Monoamine oxidase enzyme;  
 
5-HIAA  5-hydroxy indole acetic metabolite;  
 
GPCR  G protein-coupled receptor;  
 
AC   Adenylyl cyclase;  
 
cAMP  Cyclic adenosine monophosphate;  
 
PLC  Phospholipase C;  
 
PI3   Inositol triphosphate;  
 
DAG   Diacylglycerol;  
 
GIRK   G protein-coupled inwardly-rectifying potassium channel;  
 
VDCC   Voltage-dependent calcium channel; 
 
MAPK  Phosphorylated mitogen-activated protein kinase;  
 
PKC   Protein kinase C;  
 
CAMKII  Calmodulin-dependent protein kinase II;  
 
CREB   cAMP-responsive binding protein;  
 






FCI   Focal cerebral ischemia;  
 
MCA   Middle cerebral artery;  
 
MCAo   MCA occlusion;  
 
TGCI   Transient global cerebral ischemia;  
 
BCCAO  Bilateral common carotid arteries occlusion;  
 
2-VO   Two vessels occlusion;  
 
4-VO   Four-vessel occlusion;  
 
rtPA   Recombinant tissue plasminogen activator; 
 
SSRIs   Selective serotonin reuptake inhibitors; 
 
SNRIs   Serotonin-Noradrenaline reuptake inhibitors; 
   
Esc    Escitalopram 
 
BDNF   Brain-derived neurotrophic factor 
  
SYN   Synaptophysin 
  
PSD-95  Postsynaptic density protein-95  
 
NeuN   Neuronal nuclei 
 
OF   Open field test 
  
EZM   Elevated zero maze 
  
OLT   Object location test 
  
FST   Forced swim test 
 
DG   Dentate gyrus 
  
OPS   Object pattern separation 
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The 5-HT1A receptor and the ‘biased 5-HT1A agonists’ 
The serotonin type 1A (5-HT1A) receptor is an inhibitory G-protein-coupled receptor 
largely distributed throughout the central nervous system (CNS). 5-HT1A receptors 
localized in the raphe nuclei are somatodendritic autoreceptors that inhibit cell firing, with 
a consequent decrease in the extracellular levels of 5-HT in its projection areas. Post-
synaptically, 5-HT1A receptors are found in non-5-HT neurons in 5-HT projection areas, 
notably in the hippocampus, cortical areas, and amygdala. Activation of heteroreceptors 
in these brain areas induces diverse cellular responses related to emotionality and 
cognition (Albert and Vahid-Ansari, 2019). 
The 5-HT1A receptor has been subjected of intense investigation due to its involvement 
in numerous brain disorders, such as Parkinson’s disease, Alzheimer’s disease, 
depression, and anxiety (Wang et al., 2016; Garcia-Garcia et al., 2017; Albert and Vahid-
Ansari et al., 2019).  Antidepressant response (Haddjeri et al, 1998; Santarelli et al., 2003) 
and neuroprotective effects (Madhavan et al., 2003; Chilmonczyck et al., 2015; Miyazaki 
and Asanuma, 2016; also see Chapter 2) have also been linked to 5-HT1A receptor 
activation. The main pharmacological effects of 5-HT1A receptors are dependent on the 
activation of the growth factor-regulated signaling pathways, including mitogen-activated 
protein kinase mitogen-activated protein kinase (MAPK), extracellular signal-regulated 
kinase 1/2 (ERK1/2), and PI3-kinase(PI3K)-Akt-GSK3𝛽 signaling pathways (Della Rocca 
et al., 1999; Chilmonczyck et al., 2015; Albert and Vahid-Ansari, 2019).  
Several key pharmacological ligands including buspirone (the only commercialized 5-
HT1A agonist used as an anxiolytic) and 8-hydroxy-2-(di-n-propylamine)tetralin (8-
OHDPAT) have been used to characterize 5-HT1A receptor signaling and in vivo function. 
However, only moderate if any therapeutic benefit was observed with these compounds. 
The reasons for disappointing results are likely related to several factors. 5-HT1A agonists 
in general are poorly selective and may present partial agonist activity on 5-HT1A 
receptors. Buspirone, for example, may interact with 5-HT7 (Crispino et al., 2020) and 
dopamine D2 receptors (Le Foll et al., 2016). 5-HT1A receptor activation has been also 
shown to produce elements of serotonin behavioral syndrome and increase plasma levels 
of corticosterone (Koek et al., 2001).  Moreover, 5-HT1A agonists interact broadly with 5-





synaptic receptors) or regional localization.  This lack in receptor discrimination of 5-HT1A 
agonists may result in divergent or even opposite effects.  
A new generation of 5-HT1A receptor agonists, known as ‘biased agonists’, has become 
available and differentially activate 5-HT1A autoreceptors or postsynaptic 5-HT1A 
heteroreceptor in different brain regions (Newman-Tancredi, 2011). An interesting finding 
was drawn from two 5-HT1A agonists named F15599 (or NLX-101; Newman-Tancredi et 
al., 2009) and F13714 (Assie et al., 2006). Studies on their in vitro, in vivo, 
electrophysiological and neurochemical properties indicate that contrary to F13714, NLX-
101 preferentially activates post- versus presynaptic 5-HT1A receptors and influences 
cortical pyramidal neuron electrical activity at lower doses than those that inhibit raphe 
neuron firing (Depoortere et al., 2010). The biased 5-HT1A post-synaptic receptor agonist 
NLX-101 has been shown to preferentially activate the postsynaptic 5-HT1A receptor in 
cortical regions (Newman-Tancredi et al., 2009), improving cognitive performance and 
producing antidepressant- and anti-stress-like effects (Assié et al., 2010; Newman-
Tancredi, 2011; van Goethem et al., 2015; Depoortère et al., 2019).  
Notably, differential activation of 5-HT1A receptors has been proposed to be an 
attractive strategy for the management of several neurological and psychiatric conditions 
linked to pattern separation such as schizophrenia (Schreiber and Newman-Tancredi, 
2014), anxiety (Depoortère et al., 2019), Parkinson’s disease (Newman-Tancredi et al., 
2018) and cerebral ischemia (Aguiar et al., 2020). Besides, selective activation of 5-HT1A 




Cerebral ischemia is caused by the interruption of blood flow and the consequent 
lack of energy and glucose supply to the brain. Cerebral ischemia can be broadly 
categorized as either focal cerebral ischemia (FCI) or stroke, that occurs due to a 
thrombotic or embolic occlusion in a particular cerebral artery and, transient global 
cerebral ischemia (TGCI), as a result of reversible cardiac arrest. Cognitive dysfunctions, 
anxiety, and depression are prominent and long-term symptoms of transient forms of 





been related to neuronal degeneration and a decline in synaptic plasticity that are induced 
by ischemic injury in the brain (Carmichael, 2011).  
The neuropsychiatric consequences of cerebral ischemia are often under-
recognized and undertreated, even though they are highly prevalent (Jokinen et al., 2015; 
Winstein et al., 2016). Despite continuous efforts both at the experimental and clinical 
levels, the only approved pharmacological treatment has been restricted to the tissue 
plasminogen activator (tPA; National Institute of Neurological Disorders and Stroke 
Recombinant Tissue Plasminogen Activator Stroke Study Group, 1995). However, the 
narrow time window of treatment (4.5 hs) and the possible occurrence of hemorrhage 
limit its applicability to a minority of patients (Hacke et al., 2008). No other specific 
pharmacological treatment is available to treat either focal or global cerebral ischemic 
consequences. Therefore, there is a clear necessity for alternative pharmacological 
treatments, which might increase the number of patient survivors as well as the functional 
outcomes of cerebral ischemic diseases.  
Experimental models of cerebral ischemia have contributed to understanding the 
underlying disease mechanisms and the effects of several pharmacological treatments. 
In rodents, FCI can be modeled through transient or permanent occlusion of the middle 
cerebral artery (MCAo) while TGCI can be achieved by bilateral common carotid artery 
occlusion (BCCAO) or 4-vessel occlusion (4-VO) (León-Moreno et al., 2020). Despite 
particular aspects, the pathophysiological mechanisms that lead to neurodegeneration 
due to FCI or TGCI seem to be similar (Leker and Shohami, 2002). Both procedures 
induce hippocampal and cortical neurodegeneration, learning and memory dysfunctions, 
and emotional impairments (Kumaran et al., 2008; Bora et al., 2011; Rajput et al., 2011; 
Soares et al., 2013).  
From a therapeutic point of view, the selective reuptake serotonin inhibitor (SSRI) 
escitalopram (Esc)  improves clinical recovery and decreases disability in patients who 
survive cerebral ischemia (Dam et al., 1996; Zittel et al. 2008; Acler et al., 2009; Jorge et 
al., 2010; Chollet et al., 2011; Sunami et al., 2012; Mead et al., 2013; Siepmann et al., 
2015). Besides, SSRIs have been shown to restore functional behaviors, reduce neuronal 
death, exert anti-inflammatory effects, influence neurogenesis, and stimulate 





et al., 2011; Dhami et al., 2013; Espinera et al., 2013). The neuroprotective effects of 
SSRIs on brain ischemia have been related to the activation of 5-HT1A receptors (Bode-
Greuel et al., 1990; Schaper et al., 2000; Klisch et al., 2003). Thus 5-HT1A receptor 
agonists have emerged as a potential target to promote neuroprotection in ischemic 
cerebral disease (Ramos et al., 2004; Pazos et al., 2013; Johansen et al., 2014; Hind et 
al., 2016). 
 
Aging and pattern separation 
 
A decline in cognitive functions is part of normal aging (Salthouse, 2003). One of 
the most cognitive function commonly reported deficits associated with aging is memory 
loss. In particular, age-related spatial memory decline has been well-documented in both 
humans and animal models (Iachini et al., 2009; Sharma et al., 2010; Holden and Gilbert, 
2012). An important aspect of spatial memory is the ability to encode newly formed 
memories in a discrete non-overlapping fashion to reduce interference between similarly 
encoded memories (Tulving and Markowitsch, 1998). This process of discriminating 
between similar contextual memories has been referred as pattern separation (Clelland 
et al., 2009). Pattern separation performance has been used as a predictor for the 
development of cognitive impairments in pre-dementia and dementia (Reagh et al., 2013), 
anxiety disorders (Kheirbeck et al., 2012), schizophrenia (Das et al., 2014; Scheiber and 
Newman-Tancredi, 2014) and Alzheimer’s disease (Parizhova et al., 2020). 
Multiple mechanisms have been proposed to explain pattern separation but the 
exact process is not fully understood yet. The dentate gyrus (DG) of the hippocampus is 
thought to function as a pattern separator (Aimone et al., 2011; Sahay et al., 2011; Yassa 
and Stark, 2011). As such, the DG takes similar patterns of neural activity and converts 
them into distinct representations. This is thought to be achieved via dispersion of 
entorhinal cortical inputs onto the granule cells within the DG which subsequently sends 
the information to CA3 pyramidal cells (Kheirbek et al., 2012). The CA3-DG circuit of the 
hippocampus is continuously modified by the integration of newborn neurons (Miller and 
Sahay, 2019). Of note, the ablation of adult neurogenesis impairs pattern separation 





pattern separation impairments during aging in non-human primates (Small et al., 2004) 
and humans (Yassa et al., 2011).  
5-HT1A receptors, present in the hippocampal DG (Banasr et al., 2004; Radley and 
Jacobs, 2002), have been shown to interfere with spatial pattern separation (Koenig et 
al., 2008; van Goethem et al., 2015). Moreover, activation of these 5-HT1A receptors 
improves cognition via mechanisms involving adult hippocampal neurogenesis (Radley 
and Jacobs, 2002; Schreiber and Newman-Tancredi, 2014). Therefore, biased 5-HT1A 
postsynaptic receptor agonists might be a strategy for memory, in particular pattern 
separartion, improvement in age-related cognitive disorders.  
 
5-HT1A receptors and neuroplasticity 
Neuroplasticity can be defined as the brain’s ability to change, remodel, and 
reorganize when subjected to new experiences or injury (Nudo et al., 2006; Dan, 2019). 
Neuroplasticity can occur on various functional and structural levels. In the adult brain, 
neuroplasticity plays an important role in altering the state of excitability, controlling 
behavioral responses, and in the recovery of trauma. Neuroplastic processes include 
neurochemical responses that alter synaptic functions such as growth and branching of 
dendrites, remodeling of synaptic contacts, and neurogenesis (Bruel-Jungerman et al., 
2007; Drapeau and Nora Abrous, 2008; Gulyaeva, 2017). These processes are regulated 
by intracellular pathways, metabolic processes, epigenetic mechanisms, neurotrophic 
factors, and neurotransmitter systems (Mattson et al., 2018). 
Several conditions can impact neuroplasticity in brain regions related to the control 
of emotions and cognition, such as the hippocampus and prefrontal cortex (PFC). The 
hippocampus, in particular, is a brain structure with profound functional and structural 
plasticity across the lifespan in humans and rodents. This high degree of hippocampal 
plasticity, however, is as already mentioned above accompanied by a pronounced 
vulnerability to deleterious conditions such as ischemia, neuroinflammation, chronic 
stress, and aging (Bartsch et al., 2015).  
A brief episode of cerebral ischemia, for example, results in significant cell death 
in the CA1 hippocampal area which is reflected by deficits in spatial memory (Pulsinelli et 





stimulates cell proliferation in the hippocampal DG, thereby giving rise to newly generated 
neurons and supporting the activity-dependent role of adult neurogenesis in hippocampal 
plasticity (Miles and Kernie, 2008). Importantly, multiple studies indicate that 5-HT1A 
receptor signaling in the DG contributes to SSRI-mediated neurogenesis (Samuels et al., 
2015; Segi-Nishida, 2017) and promotes neuroprotective effects after experimental 
cerebral ischemia (Ramos et al., 2004; Pazos et al., 2013; Johansen et al., 2014) 
Another condition affecting hippocampal neuroplasticity is aging. Age-related 
cognitive impairments correlate with decreased synaptic plasticity such as decreased 
hippocampal neurogenesis, deficits in the maintenance of hippocampal long term 
potentiation (LTP), and reduced density of dendritic spines (Jiang et al., 2015). 
Interestingly, preferential activation of 5-HT1A postsynaptic receptors has shown 
promising results in ameliorating cognitive dysfunction (Depoortère et al., 2010), 
improving pattern separation performance (van Goethem et al., 2015), and exerting 
antidepressant- and anti-stress-like effects (Assié et al., 2010; Newman-Tancredi et al., 
2011; Depoortère et al., 2019). However, all these effects were only investigated and 
observed in healthy adult rodents. 
To summarize, based on the findings above it is interesting to investigate the 
contribution of 5-HT1A receptor activation with biased receptor agonists in improving brain 

















AIM AND OUTLINE OF THIS THESIS 
 
This thesis aimed to investigate the contribution of 5-HT1A receptor activation in 
improving brain plasticity and functional recovery in different experimental conditions. The 
biased 5-HT1A receptor agonist NLX-101 (a.k.a F15599) was used to stimulate 5-HT1A 
postsynaptic receptors in cerebral ischemia and aging animals. It was addressed whether 
the NLX-101 was more efficacious in improving brain plasticity and functional recovery in 
experimental cerebral ischemia compared to reference drugs, due to its higher selectivity 
for, intrinsic activity at, and stimulation of postsynaptic receptors in the cerebral cortex. In 
a parallel study, the involvement of the type-1 cannabinoid receptor (CB1) in the anti-
stress and neuroplasticity effects of different classes of antidepressants was investigated 
by testing Esc and Venlafaxine (VFX). 
Chapter 2 presents an overview of the 5-HT1A receptor and its potential for 
neuroprotection in cerebral ischemic diseases. Specifically, this chapter contains a brief 
description of rodent models of cerebral ischemia, the pathophysiology of cerebral 
ischemia, and the putative mechanisms underlying the effects of 5-HT1A receptor agonists 
in these conditions. Also, insights are provided into the ‘biased’ 5-HT1A receptor agonists, 
as an attractive strategy providing neuroprotection in cerebral ischemia. 
Chapter 3 deals with the question of whether the preferential 5-HT1A postsynaptic 
receptor agonist NLX-101 or the SSRI Esc mitigated cognitive and emotional impairments 
in mice subjected to the bilateral common carotid artery occlusion (BCCAO). The animals 
were treated with NLX-101 or Esc for 28 days and then evaluated in a battery of behavioral 
tests. The mice’s brains were processed to access the impact of NLX-101 and Esc on key 
proteins related to synaptic plasticity, including brain-derived neurotrophic factor (BDNF), 
synaptophysin (SYN), and postsynaptic density protein-95 (PSD-95). Dendritic 
remodeling in the hippocampus and PFC was also investigated. 
Chapter 4 focuses on the effects of acute or repeated treatment with NLX-101 in aging 
rats evaluated in the spatial object pattern separation (OPS) task. The brains were 
collected to identify neuroplasticity markers (BDNF, PSD95, SYN) and neurogenesis in 





Chapter 5 presents behavioral and neuroplasticity effects observed by repeated 
treatment with the SSRI Esc, or the selective serotonin and noradrenaline reuptake 
inhibitor (SSNRI) VFX, in chronically stressed mice. It was investigated whether the 
effects of Esc or VFX were dependent on CB1 receptor activation. For this, male mice 
were submitted to a chronic unpredictable stress (CUS) paradigm for 21 days and 
received Esc or VFX once a day, in the presence or not of the CB1 receptor antagonist 
AM251. Behavioral tests were conducted to evaluate depressive- and anxiety-like 
behaviors and the brains were collected to investigate neuroplasticity. 
Finally, in Chapter 6 a general discussion is provided, followed in Chapter 7 by a 
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THE 5-HT1A RECEPTOR AS A SEROTONERGIC TARGET FOR 





























Cerebral ischemia due to stroke or cardiac arrest greatly affects daily functioning and 
the quality of life of patients and has a high socioeconomic impact due to the surge in their 
prevalence. Advances in the identification of an effective pharmacotherapy to promote 
neuroprotection and recovery after a cerebral ischemic insult are, however, limited.  The 
serotonin 1A (5-HT1A) receptor has been implicated in the regulation of several brain 
functions, including mood, emotions, memory, and neuroplasticity, all of which are 
deleteriously affected by cerebral ischemia. This review focuses on the specific roles and 
mechanisms of 5-HT1A receptors in neuroprotection in experimental models of cerebral 
ischemia. We present experimental evidence that 5-HT1A receptor agonists can prevent 
neuronal damage and promote functional recovery induced by focal and transient global 
ischemia in rodents. However, indiscriminate activation of pre-and postsynaptic by non-
biased 5-HT1A receptor agonists may be a limiting factor in the anti-ischemic clinical 
efficacy of these compounds since 5-HT1A receptors in different brain regions can mediate 
diverging or even contradictory responses. Current insights are presented into the ‘biased’ 
5-HT1A post-synaptic heteroreceptor agonist NLX-101 (also known as F15599), a 
compound that preferentially and potently stimulates postsynaptic cortical pyramidal 
neurons without inhibiting firing of serotoninergic neurons, as a potential strategy 
providing neuroprotection in cerebral ischemic conditions. 
 








Cerebral ischemia resulting from stroke or cardiac arrest and is one of the leading 
causes of death and disability worldwide, presenting a significant global burden to 
patients, their relatives, and entire economies (Flynn et al., 2008; Benjamin et al., 2018; 
Rajsic et al., 2019). Patients who survive an ischemic cerebral insult are particularly 
vulnerable to the development of motor and cognitive impairments, depression, and 
anxiety disorders (Moulaert et al., 2010; Geri et al., 2014). Despite intense preclinical 
efforts, however, only limited advances have been made to develop effective therapies to 
promote recovery from cerebral ischemia (Ginsberg, 2009; Dirnagl and Endres, 2014).  
Serotonin 5-HT1A receptors have been implicated in the regulation of several brain 
functions such as motor function, body temperature, neuroendocrine activity, mood, 
emotion, and, memory. All these functions may be affected by cerebral ischemia. 
Besides, 5-HT1A receptors have been a target for neuroprotection in animal models of 
cerebral ischemia. However, indiscriminate activation of pre and postsynaptic by 5-HT1A 
receptor agonists may produce no therapeutic benefits in patients. The lack of receptor 
discrimination may be a limiting factor in the therapeutic efficacy of the agonists because 
5-HT1A receptors in different brain regions can mediate diverging or even contradictory 
responses. In this review, we present experimental evidence that 5-HT1A receptor 
agonists can prevent neuronal damage and promote functional recovery induced by focal 
or transient global ischemia in rodents. We also disucss the biased 5-HT1A agonis NLX-
101 (also known as F15599), a compound that preferentially and potently stimulates 
postsynaptic cortical pyramidal neurons without inhibiting serotonin neuron firing 






2. Serotonin and serotonin receptors  
Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine which is widely distributed in 
the central nervous system. As a neurotransmitter, 5-HT is involved in almost every brain's 
physiological function and plays essential roles in hormonal control, sleep, body 
temperature, appetite, mood, motor activity, and cognition (Feijó et al., 2010; David and 
Gardier, 2016; Haleem, 2019).  
Serotonergic neurons arise from the brainstem raphe nuclei, i.e., the dorsal raphe 
nucleus (DRN), median raphe nucleus (MRN), and caudal raphe nucleus (CRN) (Bang et 
al., 2012). The DRN and MRN project serotonergic fibers through the medial forebrain 
bundle (MFB) to frontal areas, while the CRN innervates cerebellar and spinal targets 
(Jacobs and Azmitia, 1992; Gaspar and Lillesaar, 2012; Maddaloni et al., 2017). Most of 
the projections that reach the DRN come from the hypothalamus, medulla, cortex, and 
amygdala. The MRN receives projections from the amygdala, prefrontal cortex (PFC), 
and other cortical areas, and mainly from the hypothalamus and midbrain (Pollak Dorocic 
et al., 2014). 
5-HT is synthesized in two steps from the essential amino acid L-tryptophan acquired 
from the diet (Fig. 1). Tryptophan is hydroxylated at position 5 to 5-hydroxytryptophan by 
tryptophan hydroxylase (TPH) is the rate-limiting enzyme, and then decarboxylated by 
the amino acid L-amino-aromatic enzyme, to 5-HT (Walther et al., 2003). Two TPH 
isoforms have been identified: TPH1 which is expressed in non-neuronal cells such as 
enterochromaffin and mast cells (Fitzpatrick, 1999), and the TPH2 isoform which is 





5-HT storage occurs in vesicles present in presynaptic neurons. Once released in the 
synaptic cleft, 5-HT may act on pre-or postsynaptic serotonergic receptors. Subsequently, 
5-HT is taken up through the serotonin transporter (SERT), into presynaptic neurons 
where it undergoes a degradation process by the monoamine oxidase enzyme (MAO) 
generating the 5-hydroxy indole acetic metabolite (5-HIAA) (David and Gardier, 2016). In 
addition to its release in projection areas, vesicular 5-HT release occurs locally in the DRN 
at somatic (Colgan et al., 2009), dendritic (de Kock et al., 2006; Colgan et al., 2012), and 
axonal sites (Bruns et al., 2000), where it modulates the activity of DRN neurons (Figure 
2). Ultrastructural studies have found somatodendritic receptors at extrasynaptic sites 
where serotonergic transmission occurs by paracrine activation by low concentrations of 
transmitter out from synapses, i.e., via volume transmission (Bunin and Wigthman, 1999; 
Courtney and Ford, 2015).  
 
 
Figure 1: Synthesis and release of serotonin (5-HT). 5-HT: hydroxytryptamine; VMAT: 
vesicular monoamine transporter; 5-HIAA: 5-hydroxy indole acetic acid; MAO: 






Serotonergic receptors are proteins that are bound to membranes and grouped 
into families according to their associated system of second messengers, their amino acid 
sequence, or their functional homology. The functional responses to 5-HT are mediated 
by 7 different families of receptors, designated 5-HT1 to 5-HT7, which are further divided 
into 15 subtypes (Hoyer et al., 1994; Bockaert et al., 2010; Hanon et al., 2008; Table 1). 
Except for the 5-HT3 ionotropic receptor, all other 5-HT receptors are classical 
metabotropic G-protein coupled receptors (GPCR) which couple to canonical signaling 
pathways through G𝛼i, G𝛼s, and G𝛼q/11 and elicit the expected second messenger 
cascades (Nichols and Nichols, 2008). The G𝛼i-coupled serotonin receptors encompass 
the 5-HT1 and 5-HT5 types, leading to inhibition of adenylyl cyclase (AC) and a 
consequent decrease of cyclic adenosine monophosphate (cAMP) levels (Lin et al., 
2002). The G𝛼q/11-coupled serotonin receptors include the 5-HT2 receptor subtypes, 
which are linked to activation of phospholipase C (PLC), producing inositol trisphosphate 
(IP3) and diacylglycerol (DAG), ultimately leading to an increase in intracellular calcium 
(Ca++) (Roth et al., 1998). 5-HT4, 5-HT6, and 5-HT7 coupled to the stimulatory G protein 
(G𝛼s) and stimulate AC and protein kinase A (PKA), leading to increased levels of cAMP 
(Polter and Li, 2010) (Table 1). Metabotropic 5-HT receptor function may also elicit non-
canonical signals that can be either mediated by a host of alternative G-proteins or be G-
protein-independent. G-protein independent signaling may involve β-arrestins which are 
associated with other signaling pathways such as the mitogen-activated protein kinases 
including extracellular signal-regulated kinase (ERK) (Schmid et al., 2008; McCorvy and 





Arrestin has been associated with GPCR desensitization (Freedman and Lefkowitz, 1996) 
and internalization (Ferguson et al., 1996), indicating the clinical importance of this 
signaling pathway to tolerance development and therapeutic efficacy of drugs (Violin et 
al., 2014).  
 




















1A, 1B, 1C 






G𝛼i/o; AC, PKA, ↓ 
cAMP 
Inhibitory De Vivo and 
Maayani, 
1986; Albert et 










G𝛼q; PLC, ↑ IP3 
and DAG 
Excitatory Roth et al., 
1998; Xu and 
Pandey et al., 
2000 




Na+, K+ ion channels Excitatory Pratt et al., 
1990; 
Chameau and 
Hooft, 2006  




G𝛼s; AC, PKA, ↑ 
cAMP 




5-HT5  raphe G𝛼i/o, ↓ cAMP Inhibitory Nelson, 2004; 
5-HT6  hippocampus, 
córtex, striatum, 
G𝛼s; AC, PKA, ↑ 
cAMP 










5-HT7  Hippocampus, 
Suprachiasmatic 
nucleus 
G𝛼s; AC, PKA, ↑ 
cAMP 




AC, adenylate cyclase; cAMP, cyclic Adenosine Monophosphate; DAG, Diacylglycerol; IP3, 
inositol trisphosphate; PKA protein kinase A; PLC, phospholipase C.  
 
3. The 5-HT1A receptor 
The 5-HT1 receptor family is divided into 6 subtypes: A, B, C, D, E, and F (Peroutka 
1988). Among all the subtypes, the 5-HT1A receptor is most studied and characterized 
because of its involvement in the pathophysiology and treatment of several psychiatric 
and neurological conditions such as anxiety, depression, Parkinson's disease, and 
Alzheimer's disease (Pazos et al., 1985; Celada et al., 2013; Garcia-Garcia et al., 2014; 
Albert and Vahid-Ansari, 2018). The induction of adult neurogenesis by antidepressants 
and remodeling of corticolimbic circuits has also been related to the stimulation of 5-HT1A 
receptors (Santarelli et a., 2003). Moreover, novel antidepressants and antipsychotics 
have begun to incorporate 5-HT1A agonist activity to enhance their therapeutic efficacy. 
Clozapine and the more recent antipsychotics aripiprazole, brexpiprazole, perospirone, 
and cariprazine, for example, exhibit partial agonist properties at 5-HT1A receptors and 
may alleviate a deficiency in dopaminergic transmission in frontocortical regions of 
schizophrenic patients, thus improving negative and cognitive symptoms. Further, 5-HT1A 
receptor activation has been shown to reduce extrapyramidal symptoms induced by 
neuroleptics (for review see Newman-Tancredi and Kleven, 2011; Celada et al., 2013). 
5-HT1A receptors can be classified into two distinct populations: presynaptic 





nuclei, and postsynaptic heteroreceptors, which exist in dendrites and cell bodies of target 
non-5-HT neurons in 5-HT projecting areas (Verge et al., 1985; Riad et al., 2000; Palacios, 
2016; Figure 2). At a presynaptic level, 5-HT1A receptor activation reduces the firing rate 
of raphe nuclei neurons, with a consequent decrease in the extracellular levels of 5-HT in 
its projection areas (Wang and Aghajanian 1977; Verge et al., 1985; Sprouse and 
Aghajanian, 1986; Meller et al., 1990; Hjorth and Sharp 1991). 5-HT1A heteroreceptors 
are located in non-serotonergic neurons, primarily in limbic areas such as the PFC, 
amygdala, septum, and hippocampus (Albert and Vahid-Ansari, 2018). In these areas, 5-
HT1A receptors are expressed in the dendrites and soma of glutamatergic pyramidal 
neurons (Riad et al., 2000) and, axon terminals of GABAergic (Freund et al., 1990; Halasy 
et al., 1992) and cholinergic neurons (Cassel and Jeltsch, 1995) which makes difficult to 
predict the effects of 5-HT1A activation on the pattern of neuronal firing (Albert and Vahid-
Ansari, 2019).  Typically, activation of heteroreceptors on distinct neurons reduces 
neuronal excitability and firing (Polter and Li, 2010). Finally, the presence of 5-HT1A 
receptors has been demonstrated in the cell body and processes of astrocytes (Whitaker-
Azmitia et al., 1993).  5-HT1A expression in astrocytes was related to neuroprotective 
effects in Parkinsonian mice (Miyazaki et al., 2013; Miyzaki and Asanuma, 2016) and 
gerbils with cerebral ischemia (Lee et al., 2014) by promoting astrocyte proliferation and 






Figure 2: Distribution of the 5-HT receptors in the central nervous system. 
 
Multiple 5-HT1A receptor signaling pathways have been identified in heterologous 
systems, but only a few of these pathways have been studied in neuronal systems. In 
general, the primary coupling linkage of the 5-HT1A receptor is linked via G𝛼i/Gαo to the 
inhibition of AC and a decrease in PKA activity (Figure 3). 5-HT1A receptors also couple 
to ion channels, via G𝛽/𝛾 subunits, activating inward rectifying potassium channel (GIRK) 
to hyperpolarize membrane potential and inhibit voltage-dependent Ca++ channels 
(VDCC) (Figure 3) (Raymond et al., 1999; Albert and Vahid-Ansari, 2018). For other 5-
HT1A receptor-G protein interactions, the G𝛽/𝛾 complex is always released, which in turn 





kinase (MAPK), ERK1/2 and also PI3-kinase(PI3K)-Akt-GSK3𝛽 signaling pathways (Della 
Rocca et al., 1999). Differences in 5-HT1A autoreceptor and heteroreceptor coupling to G 
proteins are believed to underlie different signaling and desensitization (Haleem, 2019). 
The autoreceptors are reported to mainly couple with G𝛼i while heteroreceptors are 
preferentially coupled to Gαo in the hippocampus and with both Gαo and G𝛼i in the cortex 
(La Cour, 2006). Therefore, the signaling pathway associated with the  5-HT1A receptor is 
probably determined by the precise signaling environment existing in a particular cell, 
even though the presence of other G proteins may redirect signal transduction to other 
existing pathways (Rojas and Fiedler, 2016). 
A major pathway of the 5-HT1A receptor coupled to G𝛽/𝛾 complex is the ERK1/2, 
pathway mediated by phosphorylated MAPK/ERK kinase. Hydrolysis of MAPK precedes 
the stimulation of the critical enzymes ERK1/2, which activates the transcription factor of 
the cAMP-responsive binding protein (CREB). CREB has been shown to regulate 
neuronal proliferation and survival, neurogenesis, and dendritic remodeling (Carlezon et 
al., 2005; Blendy, 2006). 5-HT1A receptor coupling to ERK1/2 is observed in the 
hippocampal-derived cell lines with endogenous expression of 5-HT1A receptors (Adayev 
et al., 1999) as well as in hippocampal tissue (Mehta et al., 2007). The 5-
HT1A/CREB/ERK1/2 pathway seems to be important for neuronal protection (Albert and 
Vahid-Ansari, 2019). Direct stimulation of 5-HT1A receptor caused elevation in the 
expression of postsynaptic density protein (PSD)-95 and dendritic spine and synapse 
formation throughout sequential activation of MAPK isoenzymes ERK1/2 and protein 
kinase C alpha (PKCα) in both a mouse neuron-derived cell line (HN2-5) and in 





2010). The same pathway PKCα/ERK1/2 augmented PSD-95 and synaptogenesis in the 
hippocampus of in vivo mice (Moghda et al., 2012). These findings indicated that PKCα 
constitutes a direct substrate of ERK1/2 in neuronal cells and might have a role in the 
neuroprotection of hippocampal neurons (Mogha et al., 2012). However, the effects of 5-
HT1A receptor activation of ERK on neurons vary and appear to depend on their location 
in different brain regions. For example, 5-HT1A receptor activation inhibits ERK1/2 
phosphorylation in RN46A cells, a model of serotonergic raphe nucleus neurons that 
express endogenous 5-HT1A receptors (Kushwaha & Albert, 2005). Besides, endogenous 
5-HT1A receptors did not couple to activation of ERK1/2 in primary cultures of rat 
hippocampal neurons (Cowen et al., 2005).  
The PI3K/Akt pathway has been found to confer neuroprotection by inhibiting apoptosis 
in several experimental conditions (Tamatani et al., 1998; Matsuzaki et al., 1999; 
Yamaguchi et al., 2001). Activation of PI3K/Akt pathway by 5-HT1A receptor resulted in 
translocation of the nuclear transcription factor-kB (NF-kB) which was required for 
inhibiting caspase 3 activation in transfected Chinese hamster ovary cells (Hsiung et al., 
2005). The PI3-K/Akt pathway has been implicated in the regulation of cell growth, 
survival, and proliferation as well as in synaptic plasticity (Kim et al., 2004). However, the 
exact mechanism of how 5-HT1A receptors couple to the PI3K pathway in neurons is still 
unclear (Albert and Vahid-Ansari, 2019).  
The signaling pathways associated with 5-HT1A receptors are probably determined by 
the precise G𝛼𝑖/𝐺𝛼𝑜  isoform existing in cells and cascades involving G𝛽/𝛾 signaling. 5-
HT1A receptor activation may impact neuronal plasticity and decrease neurodegeneration 





2015; Rojas and Fiedler, 2016; Albert and Vahid-Ansari, 2019; Sharp and Barnes, 2020). 
Of note, those signaling pathways have been suggested to be involved in neuroprotective 
mechanisms including the stimulation of nuclear factor-kB (NF-kB), inhibition of caspase 











4. 5-HT1A receptors as a potential target for neuroprotection in cerebral ischemia 
4.1. Cerebral ischemia 
Cerebral ischemia is one of the principal causes of death and disability worldwide and 
represents an increased economic burden due to treatment and post-ischemia care 
(Chamorro et al., 2016; Benjamin et al., 2018; Rajsic et al., 2019; Johnson et al., 2019). 
Cerebral ischemia occurs as a result of the transient or permanent reduction in the 
cerebral blood flow (CBF) in restricted brain regions (focal cerebral ischemia or stroke) or 
the whole brain (global cerebral ischemia). Focal cerebral ischemia (FCI) has been 
categorized as either ischemic or hemorrhagic. Ischemic stroke is caused by the 
interruption of CBF to the brain due to a thrombotic or embolic occlusion in a particular 
cerebral artery. Hemorrhagic strokes occur within the brain ruptures. Globally, ischemic 
stroke accounts for 87% of stroke cases and it is the third most frequent cause of death 
for people over 60 years old in developed countries. Hemorrhagic stroke accounts for the 
remaining 13% of patients (Chamorro et al., 2016; Johnson et al., 2019).  
Prolonged circulatory deficits may induce dramatic neuronal damage, leading to a 
broad range of neuropsychological and behavioral dysfunctions, such as motor 
impairments, cognitive deficits, and emotional symptoms (Anderson and Arciniegas, 
2010). Motor deficits are the most common symptom after stroke and are present in up 
to 77% of the patients (Lawrence et al., 2001). Studies on cognitive impairment after 
cerebral ischemia have reported rates ranging from 35% to 87% (Hoffmann et al., 2009; 
Van Rooij et al., 2016; Delavaran et al., 2017). Anxiety and post-stroke depression range 





neuropsychiatric sequelae of cerebral ischemia are disabling and can have a negative 
influence on recovery, reduce the quality of life, and lead to exhaustion of the caregivers. 
In general, stroke is characterized by an infarcted core, where cell death occurs within 
minutes after arterial occlusion and the peri-infarcted region surrounding the infarction 
named penumbra where there is a partial reduction in blood supply; this region represents 
an area to which therapeutic neuroprotective interventions can be directed (Povroznik et 
al., 2019). The nature and severity of FCI consequences depend mainly on the location 
and extent of the injury (Dugue et al., 2017).  
Experimentally, FCI can be modeled through transient or permanent occlusion of the 
middle cerebral artery (MCA) in mice or rats. MCA occlusion (MCAo) models have been 
used extensively because they reproduce the pattern of ischemic cerebral damage and 
the functional disabilities such as neurological deficits, including sensorimotor changes 
which are also often observed in many human stroke patients (Traytsman, 2003;  
Hermann et al., 2019). In general, MCAo results in a significant reduction of CBF in both 
striatum and cortex. However, the degree and distribution of blood flow reduction depend 
on the duration of MCAo, the site of occlusion along with the MCA, and the amount of 
collateral blood flow into the MCA territory (Traystman, 2003; Gennaro et al., 2019). 
These factors determine the size of the lesion. Considerable variability in the extension 
of infarct size and behavioral outcomes have been recurrent findings with this model and 
compromised in part its potential in preclinical studies (Bardutzky et al., 2005; Senda et 
al., 2005). 
Transient global cerebral ischemia (TGCI) results from unexpected reversible cardiac 





surgical procedures. Patients that survive TGCI may experience a wide range of long-
term dysfunctions, the most prominent of which are cognitive deficits, attention deficits, 
verbal communication deficiency, spatial/temporal disorientation, impaired decision-
making, anxiety, and depression (Anderson and Arciniegas, 2010). TGCI can be modeled 
through bilateral typical carotid artery occlusion (BCCAO) in mice and Mongolian gerbils 
and via two vessels (2-VO) or four-vessel occlusion (4-VO) in rats (León-Moreno et al., 
2020). Usually, TGCI affects areas of the forebrain, such as the highly vulnerable 
hippocampal pyramidal neurons (CA1 and CA3 regions), the medium-sized dorsoventral 
striatum neurons, and the pyramidal neurons in the PFC (Raval et al., 2009; Li et al., 
2011; Khodanovich and Kisel, 2015). This leads to the loss or severe impairment of brain 
functions that include motor coordination, grip strength, and cognitive and memory 
abilities. As for MCAo models, the degree of damage to the brain areas will decide the 
fate of brain functioning (Knowles et al., 2016). 
 
4.2. Pathophysiology of cerebral ischemia 
The pathophysiological mechanisms that eventually lead to the degeneration of 
cerebral tissue due to FCI or TGCI seem to be similar (Dirnagl, 1999; Leker and Shohami, 
2002; Mehta et al., 2007; Chamorro et al., 2016; Anrather and Iadecola, 2016). They 
comprise a multitude of pathways, often interconnected and overlapped, that operate at 
different time points and locations in the extra- and intracellular milieu. The chain of 
processes begins with the breakdown of ion homeostasis in the neuronal membrane, 
particularly the failure of the Na+/K+-adenosine triphosphate pump caused by the 





by presynaptic terminals, then occurs. Glutamate stimulates N-methyl-D-aspartate 
(NMDA) and α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. 
It promotes the continuous influx of Ca++, which in turn activates a series of enzymes and 
increases oxidative stress in the adjacent postsynaptic cells. These changes occur within 
minutes and comprise the excitotoxic phase of brain ischemia, with necrotic cell death in 
the infarcted core. An endogenous protective mechanism against the excess of 
membrane depolarization that is initiated by reduced energy stores is mediated by the 
ATP-sensitive K+ channel. Usually closed in normal conditions, this channel is activated 
rapidly under cerebral ischemic conditions, causing K+ efflux, limiting neuronal excitability 
and Ca++ influx, and thus blocking the subsequent neurotoxic biochemical cascade (Liao 
et al., 2010). Oxidative and nitrosative stress are partly consequences of excitotoxicity 
and result from an increase in secondary messenger systems coupled to the enzymatic 
generation of reactive oxygen species (ROS) including superoxide anions, hydrogen 
peroxide, hydroxyl radicals, and peroxynitrite (Fukuyama et al., 1998). ROS and reactive 
nitrogen species are shown to act directly as executioners of neuronal cell death during 
cerebral ischemia (Chan, 2001).  
Robust sterile neuroinflammation starts a few hours after the onset of cerebral ischemia 
and is characterized by blood-brain barrier (BBB) disruption, infiltration of peripheral 
leukocytes, activation of microglia and astrocytes, and the release of molecules known as 
damage-associated molecular patterns (DAMPs) by injured and dying cells (Liesz and 
Kleinschnitz, 2016). Activated immune cells triggered by DAMPs produce inflammatory 
cytokines, chemokines, and other cytotoxic mediators, leading to exacerbation of cerebral 





first immune cell to respond to ischemic injury is brain-intrinsic microglia, followed by 
astrocytes and neutrophils that exacerbate oxidative stress and BBB damage (Justicia et 
al., 2003). Monocytes, monocyte-derived macrophages, dendritic cells, natural killer cells, 
and lymphocytes regulate post-ischemic inflammation and may have beneficial or 
detrimental roles on cerebral injury (Liesz and Kleinschnitz, 2016).  
Concomitantly to all neurodegenerative processes, at a particular time point after 
cerebral ischemia, protective and repair mechanisms such as an increase in the 
expression of anti-inflammatory mediators and neurotrophic factors and, reactive 
angiogenesis and neurogenesis take place (Ding et al., 2008; Dirnagl, 2012; Rajkovic et 
al., 2018). In particular, the cAMP/PKA/pCREB pathway which is closely linked to synaptic 
plasticity, neurogenesis, and axon growth has been considered a fundamental process 
that is involved in the recovery of neural function following cerebral ischemic injury 
(Kitagawa 2007; Sasaki et al., 2007; Zhao et al., 2015). In vitro and in vivo experiments 
have demonstrated that the cAMP/PKA/CREB signaling pathway and the downstream 
CREB effector brain-derived neurotrophic factor (BDNF) can exert neuroprotective effects 
in ischemic brain injury. CREB expression is upregulated in the brain after MCAo 
(Salminen et al., 1995), transient global cerebral ischemia (Soares et al., 2016; Mori et 
al., 2017), and hypoxia-ischemic (HI) injury (Zaitseva et al. 2005; Carloni et al., 2010). 
Intraventricular administration of BDNF attenuated hippocampal damage after global 
forebrain ischemia (Beck et al., 1994; Wu and Pardridge, 1999) and reduced infarct size 
after MCAo (Schabitz et al., 1997) in rats. Besides, the selective serotonin reuptake 
inhibitors fluoxetine (Kim et al., 2007) and escitalopram (Lee et al., 2011) protected 





related to the upregulation of BDNF expression. Conversely, a reduction in the BDNF 
levels in the hippocampus of ischemic mice has been associated with depressive-like 
behavior induced by cerebral ischemia (Kim et al., 2016; Pang et al., 2015).   
 
5. Pharmacotherapy for cerebral ischemia 
The primary purpose of neuroprotective pharmacotherapy is to reduce the severity 
of initial damage and improve functional outcome weeks and months after a cerebral 
ischemic event. However, advances in pharmacotherapy to cerebral ischemia have been 
limited. The thrombolytic agent recombinant tissue plasminogen activator (rtPA) is the 
only FDA-approved therapy for stroke. However, the narrow time window of treatment 
(within 4.5 h of the ischemic event) and the possible occurrence of hemorrhage limits its 
applicability to a minority of patients (The National Institute of Neurological Disorders and 
Stroke rtPA Stroke Study Group, 1995). Moreover, reperfusion itself is associated with 
further neuronal damage by activation neuroinflammatory response, thus causing tissue 
injury (Dhir et al., 2020). Antiplatelet drugs, anticoagulants, and statins act as 
prophylactics and have no immediate effect following an acute ischemic attack (Tajiri et 
al., 2013). Therefore, there is a substantial need for neuroprotective strategies to prevent 
neuronal damage and promote functional recovery after cerebral ischemia.  
 
 6. Experimental evidence and putative mechanisms underlying the 







6.1. 5-HT1A agonists and MCAo models 
Studies on the involvement of the 5-HT1A receptor in cerebral ischemia advanced 
from the 1990s onwards after the development of selective 5-HT1A receptor agonists. 
Bielenberg and Burkhardt (1990) have shown the effects of acute treatment with various 
5-HT1A receptor agonists, including the full agonists 8-OH-DPAT and BayR 1531, or 
partial agonists as buspirone, gepirone, and ipsapirone, in mice and rats subjected to 
permanent MCAo (Table 2). In general, the drugs administered 30 min before or 60 min 
after MCAo and caused a significant reduction in the infarct volume in the cerebral cortex. 
Ipsapirone and Bay R 1531 reduced cortical infarct size by more than 60% as compared 
to controls.  
Neuroprotective effects have also been shown with partial agonists including CM 
57943, urapidil, S1467,1 and ipsapirone in rodents subjected to MCAo (Prehn et al., 1991; 
1993; Kamei et al., 2001; Johansen et al., 2014). Both 5-HT1A agonists CM 57943 and 
urapidil promoted a decrease in the size of infarct in the cerebral cortex of ischemic 
rodents (Table 2). Moreover, these 5-HT1A agonists were able to reduce neuronal damage 
of cultured neocortical and hippocampal neurons subjected to chemical hypoxia or 
glutamate overload in a dose-dependent manner (Prehn et al., 1993). Similarly, the potent 
5-HT1A agonist, compound 26 (2-{6-[(3,4-dihydro-2chromeen-2-
ylmethyl)amino]hexyl}tetrahydro-1H-pyrrolo[1,2c] imidazole-1,3(2H)-dione), has 
produced neuroprotective effects in both in vitro assays using primary cell cultures from 
rat hippocampus as well as in rats with MCAo (Table 1) (Marco et al., 2011). Repinotan 
was also effective in decreasing the infarct size when administered 4 h after MCAo 





In another study, Kamei et al. (2001) have demonstrated the neuroprotective effects 
of buspirone and compound 5 (SUN N 4057) in rats subjected to MCAo. In this study, the 
measurement of peripheral type benzodiazepine binding sites (PTBBS) in ipsilateral 
cortical and striatal homogenates was carried out as an index for quantification of 
neuronal damage 10 days after cerebral ischemia. A single administration of compound 
5 exerted a dose-dependent reduction of PTBBS levels and reduced the ischemic 
hyperthermia at neuroprotective doses.   
Extensive preclinical studies have been done with the full 5-HT1A receptor agonist, 
repinotan (Bay X 3702) after permanent (Semkova et al., 1998) or transient (Mauler and 
Horvat, 2005; Kukley et al., 2001) MCAo. Repinotan, when administered immediately after 
reperfusion or even 5 h later, reduced the cortical infarction volume up to 97% in rats with 
MCAo.  In vitro, the activity of repinotan was abolished by WAY 100635, indicating that 
the effect was mediated via 5-HT1A receptor stimulation. Also, repinotan elevated the level 
of the apoptosis-inhibiting protein BCL-2 in the ipsilateral cerebral cortex of ischemic 
animals, indicating a neuroprotective effect of repinotan treatment (Kukley et al., 2001).  
The favorable neuroprotective efficacy, broad dose-response curve, and prolonged 
therapeutic window observed in those stroke models positioned repinotan as a promising 
candidate for clinical trials for treating acute ischemic stroke in humans (Berends et al., 
2005). The tolerability, safety, and dose of repinotan were investigated in Phase II double-
blind, placebo-controlled study in which 240 patients with acute hemispheric ischemia 
(focal ischemia) received placebo or repinotan at 0.5, 1.25 or 2.5.mg/kg given by i.v. 
infusion during 72 h. Treatment was started within 6 h of symptoms onset and evaluations 





1.25 mg/kg/day were well tolerated with few patients requiring discontinuation, a higher 
incidence of serotonergic adverse side effects including shivering, heavy sweating, 
restlessness, agitation and confusion was detected in the 2.5 mg/kg/day dosage group 
(Teal et al., 2005). To optimize repinotan exposure of patients with stroke, a Randomized 
Exposure Controlled Trial (RECT) was design for a Phase IIB study with repinotan (Teal 
et al., 2009).  Several changes were implemented after the randomization of 98 patients 
into RECT and included: i) reduction of the allowed treatment time window from 6 to 4.5 
h to increase the potential for neuroprotective effect; ii) a loading dose to reach target 
plasma concentrations sooner; and iii) patient assignment in a 1:1 ratio to treatment with 
repinotan or placebo (changed from 2:1 in RECT). However, this study failed to 
demonstrate a clinical benefit of repinotan and the development of repinotan in ischemic 
stroke was discontinued (Teal et al, 2009). 
Finally, other preclinical results have supported the direct involvement of 5-HT1A 
receptors in neuroprotective therapies for cerebral ischemia. In this respect, cannabidiol, 
which is the second most abundant Cannabis sativa derived cannabinoid, reduced the 
infarct volume and increased the CBF in mice with MCAo. The effect of cannabidiol was 
inhibited by the 5-HT1A antagonist, WAY100635, but not by a CB1 receptor antagonist or 
by a vanilloid receptor antagonist (Mishima et al., 2005).  
 
6.2. 5-HT1A receptor agonists and TGCI models  
Transient global cerebral ischemia is characterized by an abrupt and complete 
reduction of blood flow and glucose, which causes selective neuronal injury to vulnerable 





57943, urapidil, repinotan, ipsapirone and repinotan (BAY R 1531), 15 to 30 min before 
or immediately after 2-VO resulted in a reduction of neuronal loss in the CA1 hippocampal 
subarea and entorhinal cortex  of rats (Prehn et al., 1991; 1993; Schaper et al., 2000). 
The anti-apoptotic effect of repinotan was abolished by cotreatment with the 5-HT1A 
receptor antagonist WAY100635 (Schaper et al., 2000). A 7-day infusion with the 5-HT1A 
agonist, 8-OH-DPAT, prevented the neuronal loss in the hippocampal CA1 subarea 
induced by 2-VO in rats. Hypothermia was proposed as a possible explanation for the 
neuroprotective effect of 8-OH-DPAT (Torup et al., 2000).  
Mongolian gerbils have unique vascular anatomy with no posterior communicating 
artery, which connects the carotid and vertebrobasilar arterial system. Thus, BCCAO in 
gerbils results in severe neurological signs and death of hippocampal CA1 neurons 
(Traystman, 2003). Neuroprotective effects have been detected in gerbils subjected to 
BCCAO and treated with 5-HT1A receptor agonists (Table 2). Ipsapirone, and Bay R 1531 
attenuated neuronal loss in the hippocampal CA1 region in gerbils subjected to BCCAO 
(Bode-Greuel et al., 1990; Salazar-Colocho et al., 2007; 2008). Bay R1531 showed a 
powerful neuroprotective effect with 100% preservation of neurons while gepirone and 8-
OH-DPAT were ineffective. Besides, Piera et al. (1995) have observed that 8-OH-DPAT, 
buspirone, and flesinoxan abolished the hyperactivity induced by BCCAO in gerbils. 
However, the authors found no correlation between the behavioral effects of those 5-HT1A 
agonists and the extent of their reduction in neuronal damage: only 8-OH-DPAT reduced 
neuronal degeneration induced by cerebral ischemia. It was suggested that the 
ineffectiveness of buspirone and flesinoxan may have been related to the partial agonist 





Salazar-Colocho et al. (2007, 2008) demonstrated that pretreatment with 8-OH-
DPAT increased BDNF levels and prevented the neuronal loss in the hippocampal CA1 
region of gerbils with BCCAo. Also, pretreatment with 8-OH-DPAT decreased 
phosphorylation of NMDA receptors in the hippocampus of ischemic gerbils, attenuating 
neurotoxicity and neuronal loss (Tingley et al., 1997). The authors concluded that NR1 
phosphorylation and BDNF accounted, at least in part, for the neuroprotective effects of 
pretreatment with 8-OH-DPAT. 
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7. New perspectives for targeting 5-HT1A receptors: 'biased' receptor agonists 





The studies described above and listed in Table 2 provide a clear demonstration 
that parameters associated with cerebral ischemia, can be reduced via activation of 5-
HT1A receptors. Overall, 5-HT1A receptor agonists reduced the size and infarct volume in 
the cerebral cortex of rodents subjected to MCAo and prevented hippocampal neuronal 
loss in the hippocampus of rodents with global cerebral ischemia. Such studies buttress 
the rationale for pursuing investigation of this class of compounds and suggest that they 
could lead to promising pharmacotherapeutics. Nevertheless, the clinical benefits for 
ischemia patients are currently far from impressive. The only commercialized drug in 
Table 2 is buspirone, which is commonly used as an anxiolytic though it has attracted little 
(if any) attention as a clinical anti-ischemia treatment. Interestingly it has been used as an 
anti-shivering treatment during the intervention by cooling body temperature because if 
left uncontrolled, shivering can defeat the cooling process and eliminate the potential 
benefits of therapeutic intervention in brain ischemia, see EuroHYP-1 and ICTuS2/3 trials 
on clinicaltrials.gov. Some of the other compounds, including ipsapirone and gepirone, 
are close clinical analogs of buspirone and possess similar pharmacological profiles, i.e., 
partial agonist properties at 5-HT1A receptors and some limited selectivity over multiple 
other cross-reacting sites, including dopaminergic and adrenergic receptors. Similar 
limitations also apply to urapidil and piclozotan although not to repinotan, which is potent 
and selective for 5-HT1A receptors. As surmised by Piera et al. (1995), the limited 
neuroprotective effects of at least some of the tested compounds may also be actually 
due to their insufficient agonist efficacy at 5-HT1A receptors. Thus, modest-efficacy partial 





Another important point to consider is that the tested compounds interact broadly 
with 5-HT1A receptor subpopulations throughout the brain, irrespective of neuronal or 
regional localization. This lack in receptor discrimination may be a limiting factor in the 
anti-ischemic efficacy of the agonists because 5-HT1A receptors in different brain regions 
can mediate diverging or even contradictory responses. For example, activation of 5-HT1A 
autoreceptors in the raphe inhibits serotonergic tone and dampens 5-HT release 
throughout terminal regions, thus indirectly opposing activation of postsynaptic 5-HT1A 
receptors (Figure 2). Moreover, as described above, the preferential targeting by biased 
agonist of raphe-located 5-HT1A autoreceptors or postsynaptic heteroreceptors is not due 
to differences in the receptor protein itself or binding affinity per se. The distinct responses 
to the biased 5-HT1A agonists have been attributable to regional coupling differences of 
5-HT1A receptor to certain G-protein subtypes, regulators of G-protein signaling, or 
transcriptional regulation (Newman-Tancredi, 2011). There are distinct regional 
intracellular signaling responses to postsynaptic 5-HT1A receptor activation: ERK1/2 
signaling, which is important for neuroprotective activity, varies in different brain regions 
(vide supra) and is known to be stimulated by 5-HT1A receptors in the cortex and 
hippocampus.  
Taken together, these considerations suggest that improved treatment of ischemia 
may require 5-HT1A receptor agonists that fulfill 3 conditions: (i) high receptor selectivity, 
(ii) efficacious receptor activation (full agonism), and (iii) functional selectivity for ERK1/2 
activation in vulnerable brain regions expressing postsynaptic 5-HT1A heteroreceptors. 
These criteria have not previously been met by classical 5-HT1A receptor agonists but a 





subpopulations in specific brain regions (Sniecikowska et al., 2019). An extensive series 
of in vitro, ex vivo, electrophysiological, neurochemical, behavioral, and brain imaging 
studies have shown that these 'biased agonists' differentially target 5-HT1A autoreceptors 
or postsynaptic 5-HT1A heteroreceptors in different brain regions (Newman-Tancredi, 
2011). The prototypical postsynaptic 5-HT1A receptor biased agonist is NLX-101 (also 
known as F15599), a compound that preferentially and potently activates ERK1/2 
phosphorylation and elicits cortical pyramidal neuron electrical activity without inhibiting 
serotonin neuron firing (Newman-Tancredi et al., 2009; Llado-Pelfort et al., 2010). NLX-
101 is undergoing early clinical development for breathing difficulties in Rett's syndrome 
and as a potential rapid-acting antidepressant. Indeed, NLX-101 exhibits procognitive and 
antidepressant activity in a variety of animal models (Depoortère et al., 2010; van 
Goethem et al., 2015; Depoortère et al., 2019). Notably, a recent study by Aguiar et al. 
(2020) showed that chronic treatment with NLX-101 attenuated cognitive impairments and 
despair-like behaviors induced by BCCAO in mice. Also, NLX-101 blocked the increase 
in plasma corticosterone levels and restored BDNF, synaptophysin, and PSD-95 protein 
levels in the hippocampus of mice subjected to BCCAO. These findings are significant 
because they suggest that preferential targeting of postsynaptic 5-HT1A receptors may be 
able to rescue the neurostructural damage induced by BCCAO as well as its functional 
deficits on mood and cognitive function. If these findings can be translated into a clinical 
setting, they could provide a novel basis for the development of ‘biased’ 5-HT1A 
heteroreceptor agonists in the treatment of ischemia.   
 





The primary purpose of neuroprotective pharmacotherapy is to reduce the severity 
of initial damage and improve functional outcomes in the weeks and months after a 
cerebral ischemic event. In this review, we presented experimental evidence that 5-HT1A 
receptor agonists were able to prevent the neuronal damage induced by transient focal 
or global cerebral ischemia. Indeed, over several decades abundant evidence has been 
provided that 5-HT1A receptors are involved in several processes that may attenuate 
cerebral ischemic injury at varying time points. Agonist activation of 5-HT1A receptors can 
promote hyperpolarization due to an increase in the inwardly rectifying potassium current 
and inhibit ischemia-induced excessive damage due to glutamate release. Besides, 5-
HT1A receptor agonists have been reported to exert neuroprotective effects by promoting 
hypothermia. Finally, 5-HT1A receptor agonists have been involved in the neuroplastic 
changes in the hippocampus, including an increase in BDNF and neurogenesis which are 
reduced after a cerebral ischemic event. 
Nevertheless, despite these compelling findings, little progress has been made in 
translating them into a clinical application. Most of the preclinical studies have focused on 
acute or short-term treatments, i.e., before, immediately after, or during 3 to 7 days after 
cerebral ischemia (Table 2), to promote neuronal survival. The main measurement 
(outcome) was the histological damage in vulnerable areas (cortical infarct size for MCAo 
and hippocampal cell loss for TGCI). However, the promotion of neuronal survival is of 
little therapeutic utility unless followed by successful brain remodeling and plasticity - 
which is which 5-HT1A receptor agonists produce neuroprotection need more clarification 
and systematic studies. Only two studies confirmed direct 5-HT1A receptor involvement 





5-HT1A receptor antagonist, WAY100635 (Schaper et al., 2000; Mishima et al., 2005). 
Restoring functional deficits in ischemic patients is critical for improvements in the 
patient’s quality of life and is, therefore, an important measure of a treatment's therapeutic 
potential in animal models (Liao et al., 2008; Veerbeek et al., 2011). To our knowledge, 
only two studies measured functional recovery with a 5-HT1A receptor agonist after 
cerebral ischemia (Piera et al., 1995; Aguiar et al., 2020). Interestingly, one of those 
studies indicates that the postsynaptic 5-HT1A heteroreceptor is involved in both 
neuroprotection and functional recovery, drawing attention to a possible novel and 
promising strategy for improved therapeutic intervention. A bias for postsynaptic receptors 
is important as excessive and indistinct activation of both pre- and postsynaptic 5-HT1A 
receptors may induce a broad range of physiological effects related to the expression of 
these receptors in different brain regions. Hence, as well as the desired neuroprotective 
properties, 5-HT1A receptor activation can elicit autonomic, neuroendocrine, 
neuropsychiatric, and hypothermic effects, depending on the brain regions involved. In 
this context, it is important to note that the classical 5-HT1A receptor agonists activate 
indiscriminately both 5-HT1A autoreceptors, which induce an inhibitory effect on 
serotonergic tone, and postsynaptic heteroreceptors, which are associated with inducing 
a positive effect on neuroprotective mechanisms. Such lack of functional selectivity may 
result in a limited net beneficial effect of such agonists, possibly dampening therapeutic 
efficacy and thus reducing their clinical applications. The development of a biased 5-HT1A 
receptor agonist targeting postsynaptic heteroreceptors might overcome such limitations 
and represent an attractive therapeutic strategy to provide neuroprotection in ischemic 
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Pharmacological interventions that selectively activate serotonin 5-hydroxytryptramine-
1A (5-HT1A) heteroreceptors may prevent or attenuate the consequences of brain 
ischemic episodes. The present study investigated whether the preferential 5-HT1A 
postsynaptic receptor agonist NLX-101 (a.k.a. F15599) mitigates cognitive and emotional 
impairments and affects neuroplasticity in mice that are subjected to the bilateral common 
carotid artery occlusion (BCCAO) model of brain ischemia. The selective serotonin 
reuptake inhibitor escitalopram (Esc) was used for comparative purposes. Sham and 
BCCAO mice received daily doses of NLX-101 (0.32 mg/kg, i.p) or Esc (20 mg/kg, i.p) for 
28 days. During this period, they were evaluated for locomotor activity, anxiety- and 
despair-related behaviors and hippocampus-dependent cognitive function, using the 
open field, elevated zero maze, forced swim test and object location test, respectivelly. 
The mice’s brains were processed for biochemical and histological analyses. BCCAO 
mice exhibited high anxiety and despair-like behaviors and performed worse than 
controls in the cognitive assessment. BCCAO induced neuronal and dendritic spine loss 
and decreases in the protein levels of neuronal plasticity markers, including brain-derived 
neurotrophic factor (BDNF), synaptophysin (SYN), and postsynaptic density protein-95 
(PSD-95), in prefrontal cortex (PFC) and hippocampus. NLX-101 and Esc attenuated 
cognitive impairments and despair-like behaviors in BCCAO mice. Only Esc decreased 
anxiety-like behaviors due to brain ischemia. Both NLX-101 and Esc blocked the increase 
in plasma corticosterone levels and, restored BDNF, SYN and PSD-95 protein levels in 
the hippocampus. Moreover, both compounds impacted positively dentritic remodeling in 
the hippocampus and PFC of ischemic mice. In the PFC, NLX-101 increased the BDNF 
protein levels, while Esc in turn, attenuated the decrease in the PSD-95 protein levels 
induced by BCCAO. The present results suggest that activation of post-synaptic 5-HT1A 
receptors is the molecular mechanism for serotonergic protective effects in BCCAO. 
Moreover, post-synaptic biased agonists such as NLX-101 might constitute promising 
therapeutics for treatment of functional and neurodegenerative outcomes of brain 
ischemia.  
 






Cognitive dysfunction, anxiety, and depression are prominent symptoms of 
transient forms of brain ischemia (Ayerbe et al., 2013; Moulaert et al., 2010). These 
symptoms have been related to neuronal degeneration and a decline in synaptic plasticity 
that are induced by ischemic injury in the brain (Burns et al., 2009; Carmichael, 2011). 
Many pharmacological strategies have been tested for their ability to maintain normal 
neuronal activity, attenuate excitotoxicity, decrease neuroinflammation, attenuate 
apoptotic damage, and stimulate neuroplasticity and the structural remodeling of the 
dendritic tree in several brain structures that are affected by brain ischemia (Klisch et al., 
2003; Sun et al., 2003; Tanaka et al., 2004; Schmidt and Minnerup, 2016; Sun et al., 
2017). However, no effective therapy is currently available to promote recovery following 
brain ischemia. Despite this translational dilemma, the identification of new substances 
that are safe and effective to treat the sequelae of ischemic brain damage is imperative. 
The selective reuptake serotonin inhibitors (SSRIs) such as fluoxetine, citalopram, 
and escitalopram (Esc) have been shown to improve clinical recovery and decrease 
disability in patients who survive brain ischemia (Dam et al., 1996; Zittel et al. 2008; Acler 
et al., 2009; Jorge et al., 2010; Chollet et al., 2011; Sunami et al., 2012; Mead et al., 
2013; Siepmann et al., 2015). SSRIs have also been shown to restore functional 
behaviors, reduce neuronal death, exert antiinflammatory effects, influence 
neurogenesis, and stimulate neuroplasticity in rodent models of global and focal brain 
ischemia (Kim et al., 2007; Lim et al., 2009; Lee et al., 2011; Dhami et al., 2013; Espinera 
et al., 2013). The neuroprotective effects of SSRIs on brain ischemia have been related 
to the activation of serotonin 5-hydroxytryptamine-1A (5-HT1A) receptors (Bode-Greuel et 
al., 1990; Schaper et al., 2000; Klisch et al., 2003). Thus 5-HT1A receptor agonists have 
emerged as a potential target to promote neuroprotection in ischemic brain disease 
(Ramos et al., 2004; Pazos et al., 2013; Johansen et al., 2014; Hind et al., 2016). Linked 
to this, 5-HT1A activation has been suggested to confer neuroprotection and cognitive 
improvement by influencing neurogenesis and dendritic remodeling after brain insult (Xu 






Currently available 5-HT1A agonists, however, may have a limited therapeutic 
profile. They are poorly selective, only partially activate 5-HT1A receptors (i.e. they are 
partial agonists) and they activate both inhibitory 5-HT1A somatodendritic autoreceptors 
that are located on serotonergic cell bodies in raphe nuclei, and the 5-HT1A postsynaptic 
heteroreceptors that are located in several brain regions, including the hippocampus, 
cortex, and amygdala (Pazos et al., 1985; Chalmers and Watson, 1991). Eventhough 5-
HT1A postsynaptic activation also presents inhibitory properties, it may differently 
stimulate diverse molecular signalling pathways as ERK and AKT, which can contribute 
for positive behavioral effects related to neuropsychiatric desorders (Albert and Vahid-
Ansari, 2019). Also 5-HT1A receptor activation in these different brain regions has been 
shown to produce elements of serotonin behavioral syndrome (Arvidsson et al., 1981; 
Koek et al., 2001), induce hypothermia (Cryan et al., 1999), and increase plasma levels 
of corticosterone (Koek et al., 1998). Interestingly, the preferential activation of 5-HT1A 
postsynaptic receptors has shown promising results in preclinical studies. The biased 5-
HT1A receptor agonist NLX-101 (a.k.a. F15599) has been shown to preferentially activate 
postsynaptic 5-HT1A receptors in cortical regions (Newman-Tancredi et al., 2009), 
ameliorate cognitive dysfunction (Depoortère et al., 2010), improve spatial pattern 
separation performance (Van Goethem et al., 2015), and exert potent antidepressant- 
and anti-stress-like effects (Assié et al., 2010; Newman-Tancredi et al., 2011; Depoortère 
et al., 2019). 
A pharmacological intervention that specifically activates 5-HT1A postsynaptic 
receptors may thus achieve a positive pharmacological response to brain ischemia. The 
present study investigated whether the preferential 5-HT1A postsynaptic receptor agonist 
NLX-101 mitigates cognitive and emotional impairments that are induced by brain 
ischemia in mice. We also evaluated the impact of NLX-101 treatment on key proteins 
that are related to synaptic plasticity, including brain-derived neurotrophic factor (BDNF), 
synaptophysin (SYN), and postsynaptic density protein-95 (PSD-95). In addition, we 
evaluated dendritic remodeling in the hippocampus and prefrontal cortex (PFC). To avoid 
possible short-term effects of NLX-101 on corticosterone levels as previously described 
(Assié et al., 2010), we started the drug treatments 1 week before surgery to stabilize the 





For comparative purposes, we included an experimental group that was treated with Esc, 
which has been previously shown to decrease morbidity and improve recovery in stroke 
patients and ischemic rodents (Lee et al., 2011; Siepmann et al., 2015). 
 
Material and Methods  
Animals 
Male 3-month-old C57BL/6 mice (25-30 g; n = 101) were obtained from the central 
vivarium of the State University of Maringá. The animals were acclimated to a controlled 
temperature (22 ± 1C) and a 12 h/12 h light/dark cycle (lights on at 7:00 AM) for 2 weeks 
before the experiments. The animals were housed in groups (n = 10-15/group) in plastic 
cages (39 x 32 cm, with a height of 25 cm) and given standard commercial chow (Nuvilab, 
Quimtia, PR, Brazil) and tap water ad libitum. The local Ethics Committee on Animal 
Experimentation of the State University of Maringá approved the experimental 
procedures in accordance with the guidelines of the U.S. National Institutes of Health and 
Brazilian College for Animal Experimentation (CEUA no. 7200220818). All efforts were 
made to minimize the number of animals used and their suffering. 
 
Surgery 
There are available diverse animal models to mimic some consequences of brain 
ischemic desease in humans. In this work we choose the model of bilateral common 
carotid artery occlusion (BCCAO), because it is generally applied to evaluate the effect 
of potential new treatments in neuronal injury, especially in the hippocampal and cortical 
regions, key components involved with behavioral effects of 5-HT1A postsynaptic receptor 
activation (Khodanovich & Kisel et al., 2015). Transient global cerebral ischemia was 
induced by as previously described (Soares et al., 2016). The mice were anesthetized 
with a mixture of isoflurane (Isoforine, Cristália, SP, Brazil) and oxygen through a 
universal vaporizer (Oxigel, SP, Brazil). The vaporizer was regulated to release the 
minimal burble flow (2.0 L/min). Under these conditions, the animals were fixed in a 
stereotaxic frame, and anesthesia was maintained with 1.3-1.5% isoflurane in 100% 
oxygen for 6 min, during which time an incision was made in the ventral neck to expose 





maintained at 37.5ºC using a heating blanket. BCCAO was induced for 20 min using 
aneurysm clips (ADCA, Belo Horizonte, MG, Brazil). During occlusion, the mice were 
maintained in a warming box (30ºC inner temperature) to avoid ischemia-induced 
cerebral hypothermia. At the end of each occlusion, the aneurism clips were removed, 
and the carotid arteries were visually inspected for reperfusion. Each animal was then 
anesthetized again for 2 min, and the incision was closed with sutures. Sham-operated 
animals were subjected to the same anesthetic and surgical interventions, with the 
exception that the carotid arteries remained intact. 
 
Drugs 
Escitalopram (Prati & Donaduzzi, Toledo, PR, Brazil), NLX-101 (Neurolixis, Dana 
Point, CA, USA), or vehicle (Veh; 0.9% saline) were administered intraperitoneally (i.p.) 
once daily (between 4:00 PM and 5:00 PM) for 1 week before surgery and for 21 days 
after surgery. The doses of Esc (20 mg/kg) and NLX-101 (0.32 mg/kg) were based on 
previous studies that showed positive effects regarding molecular and behavioral 
responses in rodents (Assié et al., 2010; Lee et al., 2011). All of the drug solutions were 
prepared fresh daily and injected in a volume of 10 ml/kg. The animals were randomly 
assigned to the following treatment groups in a counterbalanced order: Sham + Veh, 
BCCAO + Veh, BCCAO + Esc, and BCCAO + NLX-101. 
 
Experimental Design 
Behavioral testing was conducted from 7:00 AM to 1:00 PM. The open field test 
(OF), elevated zero maze (EZM), object location test (OLT), and forced swim test (FST) 
were performed on days 7, 8, 14, and 21 after surgery, respectively (Fig. 1). All of the 
animals’ behaviors were recorded and analyzed using the ANYmaze contrast-sensitive 
video monitoring system (Stoelting, Wood Dale, IL, USA). After behavioral testing and 24 
h after the last drug injection, all of the animals were deeply anesthetized, and blood and 







Figure 4: Experimental design. Escitalopram (Esc), NLX-101 or vehicle (Veh; saline 
0.9%), were intraperitoneal (i.p) administered one week before and during 21 days after 
sham or bilateral common carotid artery occlusion (BCCAO) surgeries. The open field 
test, (OF), elevated zero maze (EZM), object location test (OLT) and forced swimming 
test (FST) were performed at 7th, 8th, 14th and 21th days after the surgery. After behavioral 
testing, the brains were adequately removed and assayed for biochemical and 
histological analysis. 
 
Behavioral testing  
Open field test 
The OF evaluates locomotion and exploration (Gellért & Varga, 2016). The open 
field consisted of a wooden square box (70 cm  70 cm) with 40 cm high walls. On day 7 
after BCCAO, each mouse was gently taken from its home cage, immediately placed in 
the center of the open field, and allowed to explore the box for 10 min. The distance 
traveled (in meters) was recorded. 
 
Elevated zero maze 
The EZM is a modification of the elevated plus maze, with the advantage of lacking 
the ambiguous central area of the elevated plus maze (Kulkarni et al., 2007). The EZM 
test is based on two conflicting innate tendencies of rodents: exploring a novel 
environment and avoiding elevated and open spaces that constitute situations of predator 
risk. The apparatus consisted of a ring-shaped runway (46 cm diameter, 5.5 cm width) 
that was made from gray plastic material and elevated 20 cm above the floor. The runway 
was divided into two opposing open quadrants and two opposing closed quadrants with 
sidewalls (11 cm height). On day 8 after BCCAO, each mouse was individually placed on 
one of the open quadrants where it was allowed to explore the apparatus for 6 min under 





the EZM were recorded to calculate the percentage of open-quadrant entries and percent 
time in the open quadrants. 
 
Object location test 
The OLT assesses cognition, specifically spatial memory and discrimination in 
rodent models of central nervous system-related disorders. This test is based on the 
spontaneous tendency of rodents to recognize when an object has been relocated 
(Denninger et al., 2018). Testing occurs in an open field arena, to which the animals were 
first habituated. The apparatus consisted of a circular arena (43 cm diameter with 40 cm 
high walls) that was made of transparent polyvinyl chloride. Three different sets of objects 
were used, and each object was available in triplicate. The different objects were (1) an 
aluminum cube with a tapering top (4.5 cm   4.5 cm  8.5 cm), (2) a glass 200 ml bottle 
that was filled with water (5.5 cm diameter, 15.0 cm height), and (3) a porcelain cube (9.5 
cm  6.5 cm  6.5 cm). These objects were fixed within the apparatus and could not be 
moved by the mouse. One week before BCCAO, the animals were familiarized with the 
OLT, in which they were initially allowed to explore the circular arena (without any objects) 
on two consecutive days (3 min/day). On the following 4 days, the mice were trained with 
the objects until they presented stable discrimination performance, indicated by good 
object discrimination at a 1-h interval. Subsequently, BCCAO was induced, and then the 
OLT was performed on days 14 and 18 after surgery at 1 and 4 h intervals. The test 
session consisted of two trials. Each trial lasted 3 min. During the first trial (T1), the arena 
contained two identical objects. The mouse was introduced to the arena for the first 
exploration period. The animal was then returned to its home cage. After the 
predetermined time interval (1 and 4 h), the mouse was returned to the arena with the 
same objects for the second trial (T2), but one of the objects was relocated in this trial. 
The time spent exploring the two objects during T1 and T2 was recorded manually by an 
experienced observer who was blind to treatment conditions. The discrimination index 
(D2), an indication of spatial memory, was calculated to indicate whether the mouse spent 
more time exploring the relocated object, while correcting for the total exploration time in 
T2. D2 = (exploration timenovel location – exploration timefamiliar location) / (exploration timenovel 





behavior, D2 would be comparable between conditions. Exploratory behavior was 
defined as the following: the mouse directing its nose to the object at no more than 1 cm 
and/or touching the object with its nose. Sitting on the object was not considered 
exploration. Animals that explored the objects < 5 s were excluded from the analysis 
because sufficient exploratory behavior is required to achieve a reliable measure of 
memory performance. The order of the objects, which object was moved, and the position 
where the object was relocated were balanced throughout the experiment and between 
groups to reduce potential bias toward particular objects, sides, or locations. 
 
Forced swim test 
The FST is commonly used to study passive coping strategies in rodents (Can et 
al., 2012). In this task, the mice are subjected to one trial, during which they are forced 
to swim in an acrylic cylinder that is filled with water at 25°C, from which they cannot 
escape. The time that the animal spends without making any movements beyond those 
required to keep its head above water is measured. Briefly, on day 22 after BCCAO, each 
mouse was individually placed in an acrylic cylinder (10 cm diameter, 25 cm height) that 
contained enough water, so the mouse could not touch the bottom of the container or 
escape. Each session was recorded using a video camera. The latency to the first 
episode of immobility and total immobility time, during which the mouse did not struggle 
and only made movements that were necessary to keep its head above water, were 




The animals were decapitated on day 21 between 1:00 PM and 4:00 PM under 
i.p. sodium thiopental anesthesia (Thiopentax, Cristália, SP, Brazil). Blood was collected 
(n = 4/group) by puncturing the posterior vena cava and then centrifuged at 2000 rotations 
per minute for 15 min. After centrifugation, plasma was separated and stored at -80°C for 
the subsequent determination of corticosterone levels using an enzyme-linked 
immunosorbent assay (ELISA). The prefrontal cortex (PFC) and hippocampus were 





tissue buffer that contained 50 mM Tris (pH 7.6) and complete proteinase inhibitor (1:10 
dilution of stock solution; Sigma-Aldrich, St. Louis, MO, USA). After the samples were 
centrifuged at 2000 rpm, the supernatant was collected and stored at -80°C until further 
use to determine the levels of BDNF by ELISA and synaptic proteins (PSD-95 and 
synaptophysin) and NeuN by Western blot. 
 
Plasma corticosterone levels 
Plasma corticosterone levels were determined by ELISA, with the aid of an 
immunoenzymatic reaction kit according to the manufacturer’s instructions (DetectX, 
Arbor Assays, Eisenhower Place, Ann Arbor, MI, USA). Briefly, a plasma sample (5 µl) 
was treated with 5 µl of dissociation reagent for 10 min and diluted to 1:100. The samples 
were run in duplicate with a sheep polyclonal antibody against corticosterone in a 96-well 
immunoplate. A microplate reader (AsysExpert Plus, Biochrom, Berlin, Germany) was 
used to measure the intensity of immunofluorescence at 450 nm for standards and all of 
the samples. Standard curves were created using online software 
(http://www.myassays.com) and used to determine corticosterone concentrations (pg/ml) 
in the experimental samples. 
 
BDNF levels 
Total proteins of the samples were quantified using the Bradford method (Bio-Rad 
Laboratories, Hercules, CA, USA) and then analyzed by ELISA to detect BDNF using an 
immunoenzymatic reaction kit according to the manufacturer’s instructions (BDNF Emax 
ImmunoAssay System, Promega, Madison, WI, USA). Briefly, 96-well immunoplates 
were coated with monoclonal anti-mouse-BDNF antibody at 100 µl/well. After overnight 
incubation at 4ºC, the plates were washed three times with wash buffer. The samples 
were diluted 1:5 in Dulbecco’s PBS and acidified (to approximately pH 2.6) with HCl 1N 
by 15 min to be incubated in the coated wells (100 µl each) for 2 h at room temperature 
with shaking. After five additional washes, the immobilized antigen was incubated with 
an anti-human BDNF antibody for 2 h at room temperature with shaking. The plates were 
washed again with wash buffer and then incubated with anti-immunoglobulin Y (IgY) 





incubated with a TMB/peroxidase substrate solution for 15 min, and 1 M phosphoric acid 
(100 µl/well) was added to the wells. The calorimetric reaction product was measured at 
450 nm using a microplate reader (Asys Expert Plus, Biochrom, Berlin, Germany). BDNF 
concentrations (pg/µg of total protein) were determined from the regression line for the 
BDNF standard (ranging from 7.8 to 500 pg/ml purified mouse BDNF) that was incubated 
under similar conditions in each assay. All of the assays were performed in duplicate. 
 
Western blot 
Protein concentrations in the stored supernatant from the PFC and hippocampus 
were determined using the Bradford method (Bio-Rad, Hercules, CA, USA). Proteins (30 
µg from each sample well) were isolated, electrophoresed, and immunoblotted on a 10% 
sodium dodecyl sulfate-polyacrylamide gel. After protein transfer onto a nitrocellulose 
membrane (Bio-Rad, Hercules, CA, USA), the membranes were blocked (2% bovine 
serum albumin in TBS buffer) and incubated with the primary antibody at 4°C overnight 
at the following dilutions: anti-NeuN (1:500; Abcam, Cambridge, MA, USA), anti-
synaptophysin, presynaptic protein (1:2500; Millipore), anti-PSD-95, postsynaptic protein 
(1:2000; QED Bioscience, San Diego, CA, USA), and anti-GAPDH (1:2500; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). After a washing step with TBS, the membranes 
were incubated for 2 h with donkey anti-mouse IgG (1:2000; Abcam, Cambridge, MA, 
USA). Reactive bands were detected using enhanced chemiluminescence reagent 
(ECLplus, Invitrogen, Carlsbad, CA, USA) and visualized using the ChemiDoc Imaging 
System (Bio-Rad, Hercules, CA, USA). Intensities of specific bands were quantified using 
ImageJ software (National Institutes of Health, Bethesda, MD, USA) and normalized to 




Additional groups of matched C57BL/6 mice were used for Golgi-Cox staining (n 
= 7/group). Following complete anesthesia with i.p. sodium thiopental (Thiopentax, 
Cristália, SP, Brazil), the animals were transcardially perfused with 0.1 M phosphate-





in small amber tubes that contained 10 ml of Golgi solution for 24 h and incubated for 
24h at 37ºC. After this time, the Golgi solution was replaced by a new solution (10 ml), 
and the brains were stored for 20 days at room temperature while protected from light. 
Before the brains were frozen in liquid nitrogen, they were exposed to a concentrated 
sucrose solution (30%; 10 ml) and then sliced in a 1:2 series into 100 m coronal sections 
from the PFC (+3.20 to +1.70 mm from bregma; Paxinos and Franklin, 2001) to the 
ventral hippocampus (-1.34 to -3.08 mm from bregma; Paxinos and Franklin, 2001) using 
a cryostat (Criocut 1800, Reichert-Jung, Heidelberg, Germany) at -21C. The sections 
were mounted onto gelatin-coated slides. The sections were then washed with dH2O for 
5 min and alkalinized into 30% ammonium hydroxide solution in dH2O (2:1, Sigma-
Aldrich, Saint Louis, MO, USA) for 40 min. The sections were washed in dH2O for an 
additional 5 min and developed in Kodak Rapid Fix solution that was prepared according 
to the manufacturer’s instructions, with solution B omitted (catalog no. 5160353, Kodak, 
Rochester, NY, USA). The sections were washed in dH2O for an additional 5 min and 
passed through an ascending series of alcohol concentrations (50%, 70%, 95%, and 
100%) and placed in xylene for 20 min, followed by cover slipping with DPX medium 
(Fisher Chemical, São Paulo, SP, Brazil).  
Golgi-Cox impregnated neurons located in the PFC (pyramidal neurons - layers III 
and V; Fig. 5A-D) and dentate gyrus of the hippocampus (granular neurons; Fig. 5L-O) 
were analyzed using an Olympus AX-70 light microscope (Olympus, Tokyo, Japan). One 
experimenter blind to experimental conditions measured the total length of the dendritic 
tree, the number of branches and the number of dendritic spines in 30 µm- secondary 
branches, because second-order dendritic ramifications are particularly sensitive to 
plastic changes (Gould et al., 1990; Pyapali and Turner, 1994). Neurons were traced by 
ImageJ/FIJI software with NeuronJ plugin (National Institute of Health, Bethesda, MD, 
USA) according Meijering, 2010. Five neurons per animal were analyzed in different 
sections using the following criteria: the neurons were relatively isolated, displayed a 
defined cell body and a complete dendritic tree evidenced by well-defined endings, and 







SPSS 20 Statistic software (IBM® corp. Armonk, NY, USA) was used for the 
statistical analysis, and GraphPad Prism software version 6.0 (San Diego, California, 
USA) was used to graphical illustrations. To analyse the mortality rate, a proportion-like 
t-test was used to evaluate the confidence intervals to estimate the difference between 
two population proportions. Behavioral data were examined for assumptions of normal 
distribution (D’Agostino and Pearson omnibus test) and homoscedasticity (Levene’s 
test). Since behavioral data followed normal distribution and homoscedasticity, one-way 
ANOVA was used for between-group comparisons. If a main effect of group was found, 
a Newman-Keuls multiple range test was used to distinguish between them. Functional 
spatial memory within the groups, i.e., a D2 value in the OLT that differs significantly from 
0 was analyzed with a two-way one-sample t-test.  Because the results of morphological 
and molecular analysis did not attend the normal distributition and the homocedasticity 
consistently, the generalized linear model with a Poisson distribution was used for the not 
countiuous data (i.e., Golgi-cox analysis) and the generalized linear model with a Gamma 
distribution was used for the continuous data (i.e., ELISA and Western blot). Values of p 
≤ 0.05 were considered statistically significant. 
 
RESULTS 
Mortality rate  
Overall, 101 animals entered the experiment. The proportion-like t-test showed 
significant difference between Sham + Veh and BCCAO + Veh groups (p < 0.01) 
concerning the mortality rate (Table 1). No significant difference was observed with the 
BCCAO + Esc (p = 0.09) or BCCAO + NLX-101 (p = 0.92) groups as compared with 
BCCAO + Veh group, indicating that treatment with Esc or NLX-101 did not protect the 
animals from the effects of BCCAO on mortality. 
 
Table 3: Mortality Rate. A proportion-like t-test was used to evaluate the confidence 
intervals to estimate the difference between two population proportions. *p < 0.05 vs. 








Esc but not NLX-101 prevents expression of anxiety-like behaviors in BCCAO mice. 
As shown in Fig. 2A, there was no difference in the total distance traveled in the 
OF among the experimental groups (F3,35 = 0.34; p = 0.79). In the EZM test, the % of 
entries in the open quadrants of the EZM was not altered by ischemia or treatment (F3,35 
= 0.16; p = 0.91; Fig 2B). However, between-group differences appeared in the % of time 
spent in the open quadrants of the maze (F3,35 = 4.95; p < 0.01; Fig. 2C. Compared to 
sham animals, the BCCAO + Veh group presented a decrease in the % of time (p < 0.05), 
indicating anxiogenic–like effect of brain ischemia. This effect of ischemia was prevented 
by Esc (p < 0.05 vs. vehicle).  
 
Esc and NLX-101 attenuate cognitive impairments induced by BCCAO in mice 
Based on relative D2 discrimination index intervals in the OLT, ANOVA revealed 
significant effect at 1-h (F3,35 = 4.80; p < 0.01; Fig. 2D) and 4-h (F3,35 = 5.00; p < 0.01 Fig. 
2E) intervals. In both 1 and 4-h intervals, BCCAO + Veh group showed a decrease in the 
relative D2 discrimination index as compared to Sham group (p < 0.05). At 1-h and 4-h 
intervals, BCCAO + Esc and BCCAO + NLX-101 groups exhibited an increase in D2 
scores as compared to the BCCAO + Veh group (p < 0.05). We also observed that at 1-
h interval Sham + Veh (t15= 4.48; p < 0.01), BCCAO + Esc (t15 = 2.09; p < 0.05) and 
BCCAO + NLX-101 (t15 = 2.31; p < 0.05) groups showed D2 scores different from zero, 
indicating they could distinguish between the familiar and the novel location while BCCAO 
+ Veh group could not (p > 0.05). Furthermore, at 4-h interval Sham + Veh (t15= 3.21; p 
< 0.01) and BCCAO + NLX-101 (t15 = 7.99; p < 0.01) while BCCAO + Veh and BCCAO + 







Figure 5: Esc and NLX-101 promote functional recovery in BCCAO mice. (A) Open 
field task (OF). (B) Open quadrants entries (%) in the elevated zero maze (EZM). (C) % 
Time (T) in open quadrants in the EZM. (D) 1h and (E) 4h interval in the object location 
test (OLT). (F) Latency for the first episode of immobility in the forced swimming test 
(FST). Memory was evaluated by the time of finding objects using the exploration index 
D2 (D2 = 80 [scan time at the new location - scan time at the family location] / [scan time 





represent mean ± S.E.M of the different groups (n = 8, 10, 13, 8 / group, respectively). *p 
< 0.05 vs. Sham + Veh; #p < 0.05, vs. BCCAO + Veh; % D2 index ≠ 0. 
 
Esc and NLX-101 improve passive coping strategies of BCCAO mice in the FST 
ANOVA revealed significant difference in the latency for the first immobility episode 
in the FST (F3,35 = 7.94; p < 0.01; Fig. 2F). The BCCAO + Veh group presented lower 
latency when compared to Sham + Veh (p < 0.05), an effect that was reversed by Esc or 
NLX-101 (p < 0.05 vs. vehicle). 
 
Biochemical and histological analysis  
Esc and NLX-101 decrease basal plasma corticosterone levels in BCCAO mice 
The results of the plasma corticosterone levels are illustrated in Fig. 3. Significant 
differences were observed among the BCCAO groups (2 = 13.44; p < 0.05). Ischemic 
animals presented a significant elevation in the plasma corticosterone levels (p < 0.05) 
when compared to controls, while Esc and NLX-101 (p < 0.01) prevented this effect. 
 
 
Figure 6: Esc and NLX-101 decrease basal plasma corticosterone levels in BCCAO 
mice. Bars represent mean ± S.E.M of the different groups (n = 4/group). *p < 0.05 vs. 
Sham + Veh; ##p < 0.01 vs. BCCAO + Veh group. 
 
Esc and NLX-101 affect BDNF protein levels in the PFC and hippocampus of BCCAO 
mice.  
There was significant difference in the BDNF protein levels among the 
experimental groups in the hippocampus (2 = 29.56; p < 0.01; Fig. 4B), but only 





decrease in the BDNF levels in the PFC (p < 0.05) and hippocampus (p < 0.01) when 
compared to sham operated animals. In the hippocampus, the BDNF protein levels were 
restored in ischemic animals treated with both Esc (p < 0.01) or NLX-101 (p < 0.01) 
groups. NLX-101 also restored the BDNF protein levels in the PFC (p < 0.05). 
 
 
Figure 7: Esc and NLX-101 affect brain derived neurotrophic factor (BDNF) protein 
levels in the prefrontal cortex (PFC) and hippocampus in BCCAO mice. BDNF 
protein levels in the (A) PFC and (B) hippocampus. Bars represent mean ± S.E.M of the 
different groups (n = 5/group). *p < 0.05 vs. Sham + Veh; #p < 0.05, ##p < 0.01 vs. BCCAO 
+ Veh group.  
 
Esc and NLX-101 impact dendritic remodeling in the PFC and hippocampus of BCCAO 
mice.  
Fig. 5 shows the results of dendritic remodeling in ischemic mice after Esc or NLX-
101 treatment in PFC and hippocampus. In the PFC, there were significant differences 
among experimental groups concerning the total dendritic length (2 = 367; p < 0.01; Fig. 
5I) and number of apical (2 = 10.74; p < 0.05; Fig. 5K) and basilar (2 = 7.53; p < 0.05; 
Fig. 5K) spines in the pyramidal neurons. Compared to Sham + Veh group, BCCAO mice 
presented a significant reduction in the total dendritic length (p < 0.01) which was 
prevented by Esc or NLX-101 treatment (p < 0.01). Also, BCCAO induced a decrease in 
the number of apical and basilar spines as compared to controls (p < 0.05). Esc or NLX-
101 treatment did not affect the loss of apical spines in BCCAO mice (p > 0.05). However, 
ischemic animals that received Esc or NLX-101 presented a partly attenuation of the loss 









Figure 8: Esc and NLX-101 changes the dendritic remodeling in the prefrontal 





Representative photomicrographies of pyramidal neurons and dendritic spines in the 
PFC (20 and 100x magnification). (I) Total length of dendritic tree, (J) number of branches 
and (K) number of dendritic spines in 30 µm-secondary branches of pyramidal neurons 
in the PFC. (L-S) Representative photomicrographies of granular neurons and dendritic 
spines in the DG of hippocampus (20 and 100x – magnification). (T) Total length of 
dendritic tree, (U) number of branches and (V) number of dendritic spines in 30 µm-
secondary branches of granular neurons in the DG. Bars represent mean ± S.E.M of the 
different groups (n = 7/group). *p < 0.05 vs. Sham + Veh; #p < 0.05, ##p < 0.01 vs. BCCAO 
+ Veh group. 
 
In the hippocampus, there were significant differences regarding the total dentritic 
length (2 = 278.05; p < 0.01; Fig. 5T) and number of spines (2 = 22.2; p < 0.01; Fig. 5V) 
in the granular neurons. BCCAO + Veh group showed a decrease in the total dentritic 
length as compared to Sham + Veh group (p < 0.01). Esc or NLX-101 prevented the 
effects of BCCAO in the total dendritic length (p < 0.01). Esc also induced an increase in 
the number of spines in BCCAO mice when compared to controls (p < 0.01).  
No significant differences were observed among the experimental groups 
concerning the number of branches in the PCF (2 = 2.37; p = 0.49; Fig. 5J) or 
hippocampus (2 = 0.66; p = 0.88; Fig. 5U). 
 
Esc and NLX-101 effects on neurodegeneration and synaptic plasticity in BCCAO 
animals. 
In the PFC, Western blot analysis revelead differences in the protein levels of PSD-
95 (2 = 33.19, p < 0.01; Fig. 6D) while no differences were detected in the levels of NeuN 
and SYN (2 = 3.23 - 3.47; p > 0.05; Fig. 6B and C, respectively) among the experimental 
groups. BCCAO mice presented a decrease in the levels of PSD-95 protein when 
compared to Sham animals (p < 0.01), an effect that was attenuated by Esc treatment (p 
< 0.05 vs. vehicle). 
In the hippocampus, a main effect of groups for the levels of NeuN (2 = 13.33; p 
< 0.01; Fig. 6F), SYN (2 = 15.09; p < 0.01; Fig. 6G) and PSD-95 (2 = 17.24; p < 0.01; 
Fig. 6H). Compared to sham-operation, BCCAO induced a decrease in the NeuN (p < 
0.01), SYN (p < 0.05) and PSD-95 (p < 0.01) protein levels. Both Esc and NLX-101 





p < 0.05) and PSD-95 (Esc, p < 0.05 and NLX-101 p < 0.01) protein levels when 
compared to ischemic animals that received Veh.  
 
Figure 9: Esc and NLX-101 effects on neurodegeneration and synaptic plasticity in 
the prefrontal cortex (PFC) and hippocampus in BCCAO animals. Representative 
blots of neuronal nuclei (NeuN), synaptophysin (SYN) and postsynaptic density protein-
95 (PSD-95) proteins in the (A) PFC and (E) hippocampus. Protein levels of NeuN, SYN 





the different groups (n = 5-6/group). *p < 0.05 vs. Sham + Veh; # p < 0.05, ##p < 0.01 vs. 
BCCAO + Veh. 
 
Discussion 
In the present study, we found that BCCAO induced anxiety-like behavior, 
impaired hippocampus-dependent cognitive function, and increased despair-like 
behavior in mice. Decreases in the protein levels of NeuN, BDNF, SYN, and PSD-95 
were detected mainly in the hippocampus or some of that in the PFC in ischemic mice. 
Moreover, BCCAO provoked damage in dendritic structures in those vulnerable brain 
regions. The biased 5-HT1A receptor agonist NLX-101 (a.k.a. F15559), attenuated 
cognitive impairments and despair-like behaviors that were induced by brain ischemia. In 
addition to its behavioral effects, NLX-101 restored the levels of SYN and PSD-95 in the 
hippocampus of ischemic mice. In general, NLX-101 and Esc increased the BDNF protein 
levels and impacted neuronal morphology in both hippocampus and PFC of BCCAO 
mice. Esc decreased anxiety-like behaviors and attenuated the reduction of PSD-95 
protein levels in the PFC of BCCAO mice. As NLX-101 was not effective on these 
measures, this suggests that PFC postsynaptic 5-HT1A receptoprs are likely not fully 
involved in mediating these effects of Esc.  Both NLX-101 and Esc blocked the increase 
in basal plasma corticosterone levels that was induced by BCCAO. The present results 
indicate that NLX-101 might also counteract functional and neurodegenerative outcomes 
of brain ischemia in mice. 
5-HT1A receptor agonists may elicit differential and sometimes opposing 
responses in rodents. In behavioral tests, for example, anxiolytic-like effects have been 
related to 5-HT1A autoreceptor activation, whereas antidepressant-like activity has been 
shown to be mediated by the activation of 5-HT1A postsynaptic receptors (Celada el al., 
2013; Garcia-Garcia et al., 2014 Depoortère et al., 2019). These different responses 
occur because 5-HT1A agonists generally indiscriminately activate 5-HT1A receptors in 
different brain regions and different signaling pathways (Newman-Tancredi et al., 2011). 
In the present study, we compared the effects of two compounds, NLX-101 (a biased 
agonist that preferentially activates postsynaptic 5-HT1A receptors) and Esc (a SSRI that 
blocks the serotonin transporter), resulting in indistinct increases in extracellular 5-HT 





cognitive performance in the OLT and prevented the expression of anxiety- and despair-
like behavior in ischemic animals. NLX-101 improved memory performance and 
prevented behavioral dispair. These data are in accordance with previous studies 
showing that NLX-101 exerts antidepressant-like and pro-cognitive effects in rodents 
(Depoortère et al., 2010; Newman-Tancredi et al., 2011; Van Goethem et al., 2015). Of 
note, NLX-101 has been shown to have positive effects in a pattern separation task 
implicated in episodic memory (Van Goethem et al., 2015) and to alleviate the detrimental 
effects of phencyclidine on memory in rats in the hole-board test when acutely injected 
(Depoortère et al., 2010). Importanly, the acute effects of NLX-101 on cognition was not 
shared by the non-biased 5-HT1A agonist 8-OHDPAT, or by the preferential presynaptic 
5-HT1A receptor agonist, F13714 (Depoortère et al., 2010).  
Brain ischemia is followed by an increase in corticosterone secretion, which may 
exacerbate brain damage. Several studies have shown that preventing the rise in basal 
corticosterone levels that is induced by brain ischemia can increase cell survival and 
preserve synaptic function (Sapolsky and Pulsinelli, 1985; Morse and Davis, 1990; 
Krugers et al., 1998; Krugers et al., 2000). We observed a decrease in blood 
corticosterone levels with Esc and NLX-101 treatments in BCCAO mice. These results 
indicate that repeated treatment with both Esc and NLX-101 may modulate hypothalamic-
pituitary-adrenal axis function in mice with brain ischemia. 
In the present study, we observed a decrease in BDNF levels in the PFC and 
hippocampus in BCCAO mice. Treatment with Esc increased BDNF levels in the 
hippocampus in BCCAO mice. These results are consistent with previous studies that 
showed that SSRIs, such as fluoxetine (Kim et al., 2007) and Esc (Lee et al., 2011), 
increased BDNF immunoreactivity and protein levels in the hippocampus in gerbils that 
were subjected to transient global brain ischemia. Additionally, Espinera et al. (2013) 
found that citalopram increased the expression of BDNF in the peri-infarct region in mice 
with focal brain ischemia.  In the present study, repeated treatment with NLX-101 restored 
BDNF levels in the PFC and hippocampus in BCCAO mice to sham levels. To our 
knowledge, no previous study assessed the effects of NLX-101 on BDNF expression in 
the ischemic brain. BDNF is a neurotrophic factor that plays an important role in 





Favorable effects of BDNF on functional recovery and neuroplasticity after brain ischemia 
have been reported (Schäbitz et al., 2007; Espinera et al., 2013; Soares et al., 2016). 
The present results suggest that the effect of NLX-101 on BDNF levels may be 
associated with neuroprotective effects after ischemic insult. 
The hippocampus and PFC play a central role in spatial learning and memory, 
which have been closely related to the plasticity of dendritic arborization and 
morphological changes such as expansion and contraction (Knafo et al., 2004; Frankfurt 
and Luine, 2015; Milner and Klein, 2016). Dendritic spines are an active site of 
neuroplasticity, including synaptogenesis and synaptic remodeling (Spruston, 2008). 
Brain ischemia has a profound effect on the structure and function of synapses that is 
associated with impairments in neurological function (Hasbani et al., 2000). The loss of 
hippocampal neurons and synapses following brain ischemia have been related to 
cognitive impairments, including poor spatial memory performance (He et al., 2012). 
Notably, these neuroplastic responses can be stimulated by pharmacological 
interventions. For example, a single intravenous injection of melatonin mitigated the loss 
of dendritic spines of pyramidal neurons in the PFC and hippocampus that survived for 
up to 120 days after transient global brain ischemia (González-Burgos et al., 2007; 
García-Chávez et al., 2008). Similar recovery of dendritic spines was conferred by 
treatment with progesterone and allopregnanolone (Moralí et al., 2012), which also 
alleviated learning and memory deficits that were caused by ischemia (Moralí et al., 
2011). Ischemia-induced dendritic spine deterioration in the hippocampus was prevented 
by acetyl-L-carnitine administration before and after ischemia, an effect that paralleled 
the normalization of hippocampal long-term potentiation, indicating the improvement of 
synaptic function at dendritic spines (Kocsis et al., 2014). In the present study, BCCAO 
mice exhibited significant dendritic spine loss in cortical neurons but not in hippocampal 
neurons that survived up to 21 days of brain ischemia. The reason for this regional 
difference in the effects of BCCAO on dendritic spine density is unknown but may be 
related to the duration and degree of neuronal vulnerability to damage after brain 
ischemia (Zhu et al., 2017). Both Esc and NLX-101 increased the levels of BDNF in the 
hippocampus and PFC (except for Esc) in ischemic mice. The ability of NLX-101 to 





preliminary evidence that it can play a role in regulating synaptic plasticity in mice with 
brain ischemia. 
The stimulation of endogenous mechanisms that are related to plasticity may 
confer functional recovery and neuroprotection after brain ischemia (Chen et al., 2005; 
Cui et al., 2013; Ishrat et al., 2015). Both SYN and PSD-95 are the main proteins that 
participate in structural synaptic plasticity (Sadigh-Eteghad et al., 2018). SYN is a marker 
of pre-synapse development and activity (Yong et al., 2014), and PSD-95 is an essential 
factor for synaptic plasticity and postsynaptic membrane stabilization (Luo et al., 2013). 
The expression of SYN and PSD-95 markedly decreases in the hippocampus after 
experimental brain ischemia (Ishimaru et al., 2001; Zhao et al., 2011; Yan et al., 2013). 
In the present study, likewise PSD-95 levels decreased in the PFC and hippocampus 
after BCCAO. A decrease in the levels of SYN was observed in the hippocampus in 
BCCAO mice, which was restored by Esc or NLX-101 treatment. The relevance of these 
findings is underscored by the fact that PSD-95 regulates the strength of excitatory 
neurotransmission (Blanpied et al., 2008), and the recovery of PSD-95 levels may 
determine the degree of functional recovery after an ischemic insult. Furthermore, in the 
hippocampus this recovery is related to postsynaptic 5-HT1A receptor, while these 
receptors appear to play a minor role in the PFC in this respect. 
 
Conclusion 
In summary, the protective effects of Esc and NLX-101 on cortical and 
hippocampal neurons paralleled with their restorative or stimulating effect on the 
expression of BDNF, SYN and PSD-95, suggesting a relationship between these 
proteins, dendritic remodeling, and functional recovery after BCCAO. Moreover, the 
overall similarity in the effects of Esc and NLX-101 suggests that the protective effects of 
SSRIs in BCCAO are mediated specifically by activation of post-synaptic 5-HT1A 
receptors, especially in the hippocampus. Direct targeting of this receptor subpopulation 
with biased agonists such as NLX-101 may constitute a new strategy for therapeutic 
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NLX-101, A BIASED 5-HT1A RECEPTOR AGONIST, IMPROVES PATTERN SEPARATION 
AND STIMULATES NEUROPLASTICITY IN AGED RATS. 





















INVOLVEMENT OF THE TYPE-1 CANNABINOID RECEPTOR (CB1) IN THE ANTI-






























Several pieces of evidence suggest that the monoaminergic theory of depression cannot 
fully explain the behavioral and neuroplastic changes observed after antidepressant 
chronic treatment. Other molecular targets, such as the endocannabinoid system, have 
been associated with the chronic effects of these drugs.  In the present study, we 
hypothesized that the behavioral and neuroplastic effects observed after repeated 
treatment with the antidepressants escitalopram (Esc) or venlafaxine (VFX) in chronically 
stressed mice depend on CB1 receptor activation. Male mice submitted to chronic 
unpredictable stress (CUS) paradigm for 21 days were treated with Esc (10mg/Kg) or 
VFX (20 mg/kg) once a day in the presence or not of AM251 (0,3 mg/Kg), a CB1 receptor 
antagonist/inverse agonist.  At the end of the CUS paradigm, we conducted behavior 
tests to evaluated depressive- and anxiety-like behaviors. Our results demonstrated that 
chronic blockade of the CB1 receptor by AM251 attenuated the antidepressant- but not 
the anxiolytic-like effects of Esc. AM251 decreased the pro-proliferative effects of Esc in 
the dentate gyrus. It also attenuated the increase in CB1 and PSD-95 expression in the 
hippocampus. AM251, however, failed to modify the antidepressant and anxiolytic effects 
of VFX.  Our results suggest that CB1 receptors are not involved in the anxiolytic-like 
effects observed after repeated antidepressant treatment in animals submitted to CUS. 
However, CB1 receptors seem to participate in the antidepressant-like effects of selective 
serotonin reuptake inhibitors observed in this model. This anti-stress effect was 
associated with hippocampal neuroplastic changes.  
 














A large body of research has suggested that stressful experiences play a crucial 
role in the development of psychiatric disorders such as anxiety and major depressive 
disorder (MDD) (Heim & Nemeroff, 1999; Hammen, 2005; McEween, 1998; Maydaych, 
2019). Antidepressants (ADs) such as selective serotonin reuptake inhibitors (SSRI) or 
the selective serotonin and noradrenaline reuptake inhibitors (SSNRI) are the first-line 
treatments for anxiety disorders, MDD, and other stress-related disorders. The clinical 
use of these drugs, however, is hindered by problems such as side-effects, late onset of 
therapeutic actions, incomplete remission of the symptoms, or even treatment-resistance 
(Cipriani et al., 2018). 
Over the years, numerous groups have been trying to understand why ADs take 
weeks for the beginning of their therapeutic effects. Blier and colleagues suggested that 
the clinical improvement observed after chronic treatment with ADs depends on the 
desensitization of the type 1A serotonergic receptors (5-HT1A) located in the soma of the 
neurons in raphe nuclei (Blier & De Montigny, 1994; Blier, 2001). Other proposed 
hypotheses focused on ADs-induced neuroplastic changes involving hippocampal 
neurogenesis and dendritic remodeling (Santarelli et al., 2003; Bessa et al., 2009). 
Although these proposals are mostly based on the classical monoaminergic theory of 
depression, several pieces of evidence indicate that other neurotransmitter systems are 
involved. Among them, the endocannabinoid system could also be involved in the 
therapeutic effect of ADs (Hill et al., 2006a, 2006b; 2008; 2009). 
The endocannabinoid system includes the CB1 and CB2 cannabinoid receptors, 
and the endocannabinoid ligands, anandamide (AEA) and 2-arachidonylglycerol (2AG) 
(Matsuda et al., 1990; Devane et al., 1992; Munro et al., 1993; Mechoulam et al., 1995). 
Endocannabinoids are classically defined as neuromodulators produced on demand from 
membrane phospholipids by specific enzymes widely expressed in the central nervous 
system (Thomas et al., 1997). Chronic antidepressant treatment positively modulates the 
expression of CB1 receptors and the levels of endocannabinoids (AEA and 2 AG) in the 
hippocampus and prefrontal cortex (PFC), brain areas involved in the control of 





genetic manipulations of the endocannabinoid system impact serotonin function in the 
PFC and dorsal raphe nucleus (Bambico et al., 2009).  
Serotonin and endocannabinoids play an important role in neuroplastic changes 
associated with depression such as dendritic remodeling and adult neurogenesis 
(Aguado et al., 2005; Jiang et al., 2005; Campos et al., 2013). However, the possible 
connection between chronic stress, ADs behavioral effects, neuroplasticity, and 
endocannabinoid systems is not yet been fully investigated (Fogaça et al., 2013).  
In the present work, we tested the hypothesis that the endocannabinoid signaling, 
via the CB1 receptor, participates in the behavioral and neuroplastic effects caused by 
two antidepressants, escitalopram (Esc, a SSRI), and venlafaxine (VFX, a SNRI), in mice 
exposed to chronic unpredictable stress (CUS).  
 
Material and Methods 
Animals  
 Adult male C57BL6 (8-10 weeks old at the beginning of the protocols) derived from 
the colony of the Central Animal House of the University of São Paulo, Ribeirão Preto 
Campus (experiments conducted with Esc) and from the colony of the Multidisciplinary 
Center for Biological Investigation on Laboratory Animal Science- Campinas State 
University (experiments conducted with VFX) were used. Mice were allowed to 
acclimatize for at least two weeks in our animal facility before the beginning of the 
experiment. During the whole period (from their arrival until the end of the experiments), 
the animals were kept in a quiet room with controlled temperature and humidity 12:12 h 
light/dark cycle (lights on at 6:30 am) and had free access to food and water (except for 
short periods during the stress protocols). Mice were randomly divided into stressed and 
non-stressed groups, housed in separate cages, and arbitrarily assigned to the 
pharmacological treatments. Each stress procedure as well as the behavioral tests were 
carried out in separate quiet rooms. The Ethical Committee of Animal Experimentation of 
the Ribeirão Preto Medical School (FMRP)- USP approved the experimental protocols 







The CB1 inverse agonist, AM251 (Tocris Bioscience, Bristol, UK), the SSRI, Esc and, 
the SSNRI VFX (Prati & Donaduzzi Cia. Ltda, PR, Brazil) or vehicle [Veh, Tween 20 1% + 
DMSO 0.2 % (v/v)] in saline 0.9% (w/v), were intraperitoneal (i.p) administered during 21, 
between 4:00 p.m. and 5:00 p.m. The 5-Bromo-2-deoxyuridin (BrdU) (Sigma-Aldrich, 
Missouri, USA - 200 mg/kg in saline 0.9%, w/v) was i.p administered one day before the 
sacrifice. The AM251 (0.3 mg/kg), VFX (20 mg/kg) and Esc (10 mg/kg) doses were based on 
previous studies (Campos et al., 2013; Seo et al., 2017). All solutions were freshly prepared 
and injected in a volume of 10 ml/kg. 
 
Experimental Design  
 
Experiments I (Esc): the experiments were conducted as described in Figure 1. 
Independent groups of animals were submitted (or not) to the CUS paradigm for 21 days.  
During the CUS protocol, mice received i.p. injections of Veh or AM251 followed by Veh 
or Esc once a day with an interval of 30 min between each treatment. The injections were 
performed 6 h after the daily stressor. The following groups were generated: Veh + Veh 
(non-stressed); chronically stressed (CUS): Veh + Veh; Veh + Esc; AM251 + Veh; AM251 
+ Esc. On day 19th, 15 h after the daily stressor and drug treatment, mice were exposed 
to the open field task (OF) (tests started at 8:00 a.m) to evaluate the locomotor activity. 
In the afternoon (test started at 1:00 p.m) of the same day, the animals were submitted 
to the tail suspension test (TST) to evaluate coping behaviors. On day 21st, the last day 
of daily stressors, the animals received a single i.p. injection of BrdU (200 mg/kg) to 
evaluate cell proliferation in the dentate gyrus of the hippocampus. On day 22nd, 24 h 
after the last drug administration, 20 h food-deprived mice were submitted to the novelty 
suppressed feeding (NSF) test to evaluate anxiety-like behavior. Brains were harvested 
immediately after the end of the last behavioral task for western blot, ELISA or 
immunohistochemistry/fluorescence assays.   
 
Experiment II (VFX): the experimental design was similar to the experiments conducted 
with Esc. The following groups were generated: Veh + Veh (no stressed); chronically 





stress protocol, mice were submitted to the ST in the morning period. On day 22nd, about 
24 h after the last drug treatment, the animals were submitted to the NSF test.  
 
 
Figure 1. Timeline of the experimental designs used in experiments 1 and 2. D: day; OF 
open field; TST: tail suspension test; ST: splash test; NSF: novelty suppressed feeding.  
 
Protocols: 
Chronic Unpredictable Stress 
 During the light period of the cycle, mice were submitted to the CUS paradigm 
(Campos et al., 2013) for 21 consecutive days. Different daily mild stressors were 
randomly used: bedding alterations (sawdust removal, exposure to wet sawdust for 24h); 
food deprivation for 24 h, the reversal of the light/dark cycle, forced swimming (15 min), 
inclined box overnight, restraint stress (2h). All efforts were made to minimize animal 
suffering during the procedures. We have carefully performed screenings of all animals 
for any injury or signal of disease.  
 
Open field (OF) 
The OF test is widely used to evaluate locomotion and exploratory behavior 
(Seibenhener and Wooten, 2015). The circular OF was made of transparent acrylic (50 
cm high wall, and 40 cm of diameter). The floor was made of white acrylic. On the day of 
the test, each mouse was gently removed from its home cage and put immediately in the 
center of the OF. They were allowed to explore the arena for 10 min freely. All trials were 
recorded and analyzed automatically (in a live mode) by the AnyMaze software (Stoelting, 







Tail-suspension test (TST) 
           The TST, a classical animal model used to evaluate passive and active coping 
behavior, was a modified version of that validated in mice by Steru and colleagues (1985). 
On the day of the experiments, all experimental groups were transported from the housing 
facility to the testing room. Then, they were left there undisturbed for at least three h. 
Animals were individually suspended by the tail to a horizontal ring-stand bar (distance 
from floor = 35 cm) using an adhesive tape (distance from the tip of tail = 2 cm). Typically, 
mice demonstrated several escape-oriented behaviors interspersed with bouts of 
immobility of increasing length as the session progressed. The test session (6 min) was 
recorded, and the total immobility time was measured by an experienced experimenter 
blind to the treatment conditions. 
 
Novelty suppressed feeding test (NSF) 
           The NSF test is another classical test employed to evaluate anxiety-like behaviors 
(Campos et al., 2013). The apparatus consisted of a square acrylic box (40 x 40 x 30 cm) 
with the floor covered by 2 cm of sawdust. Twenty-four hours before the test, all animals 
were food-deprived. On the day of the test, a single regular chow pellet was placed on a 
white platform located in the center of the arena. Each animal was placed in one of the 
corners of the apparatus, and the latency to start to eat in the new environment was 
measured in a 10 min test session. The stopwatch immediately stopped when the mouse 
bites the chow, using its forepaws and sitting on its haunches. After the test, all animals 
returned to their home cages and the amount of food consumed in the next 5 minutes 
was measured. 
 
Splash Test (ST) 
The ST consists of splashing a sucrose solution (10%) on the mice's dorsal coat 
in its home cage. After applying the sucrose solution the time spent in a 10 min test 
session behavior was recorded for 6 min to evaluate the self-care and hedonic behavior. 
The sucrose solution has sufficient viscosity to evoke self-cleaning behaviors or 
grooming. Mice exposed to CUS exhibit an impairment in self-cleaning behaviors. Chronic 





al.; 2004). Grooming reduction has been correlated with symptoms of MDD such as 
apathy and reduced self-care. An experimenter blind to the treatment conditions carried 
out the behavior analyses manually by watching the videos. In the ST, the latency for the 
grooming first episode after the splash of the sucrose solution in the mice's neck was 
recorded. The total grooming time, specifically in the face, was analyzed between the 1st 
and the 6th minute of the test.  
 
Tissue preparation 
Soon after the last behavioral assessment, the animals were euthanized under 
anesthesia (Ketamine/Xylazine 100/8 mg/Kg 0.1 ml, i.p., Syntec, Brazil). The 
hippocampus was rapidly dissected (n = 4-6 per group), according to Spijker et al. (2011). 
After that, the samples were lysed in a tissue buffer containing 50 mMTris (pH 7.6) and a 
complete proteinase inhibitor (1:10 dilution of stock; Sigma-Aldrich, St. Louis, MO, USA). 
After homogenization, the supernatant was collected and stored separately at −80 °C until 
further use.  
For immunohistochemistry, mice were perfused transcardially with phosphate 
buffer saline (PBS), followed by a 4% paraformaldehyde solution for tissue fixation. After 
that, brains were removed, cryoprotected for 72 h in a 30% sucrose solution, and cut in 
slices of 30 µm at the hippocampus region (bregma from -1.46 to – 3.08 mm; Paxinos & 
Franklin, 2001) using a cryostat (Criocut 1800, Reichert-Jung, Heidelberg, Germany). 
 
Determination of BDNF levels by ELISA 
The dissected hippocampus was processed in a lysis buffer (50 mMTris (pH 7.6) 
enriched with a proteinase inhibitor cocktail (1:10 dilution of stock; Sigma-Aldrich, St. 
Louis, MO, USA) in a Tissuelyser (Qiagen, Hilden- Germany). After the lysing procedure, 
samples were centrifuged twice (10 min, 12000 rpm), and the supernatant collected and 
store at -80°C until the begging of the analysis. The samples' total proteins were 
quantified using the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA). 
Proteins extracted from hippocampal samples were submitted to ELISA protocols to 
detect BDNF according to the manufacturer's instructions (BDNF Emax Immunoassay 





monoclonal anti-mouse-BDNF antibody at 100 µl/well. After overnight incubation at 4ºC, 
the dishes were washed three times with wash buffer. The samples were diluted 1:5 in 
Dulbecco's PBS, acidified (to approximately pH 2.6) with HCl 1N by 15 min, and incubated 
in the coated wells (100 µl each) for 2 h at room temperature with shaking. After five 
additional washes, the antigen was immobilized with an anti-human BDNF antibody for 2 
h at room temperature with shaking. The plates were rewashed with wash buffer and then 
incubated with anti-immunoglobulin Y (IgY) horseradish peroxidase for 1 h at room 
temperature. After another wash, the plates were incubated with a TMB/peroxidase 
substrate solution for 15 min, and 1 M phosphoric acid (100 µl/well) was added to the 
wells. The calorimetric reaction product was measured at 450 nm using a microplate 
reader (Victor, Perkin Elmer, MA, United States). BDNF concentrations (pg/µg of total 
protein) were determined from the regression line for the BDNF standard (ranging from 
7.8 to 500 pg/ml purified mouse BDNF) that was incubated under similar conditions in 
each assay. All assays were performed in duplicate. The final results were expressed 
against the total protein concentrations.  
 
Western blot 
The protein concentrations in the stored supernatant from the hippocampus were 
determined using the Bradford method. Twenty micrograms/20mL of total proteins were 
electrophoresed (NuPAGE, Invitrogen, CA, USA). After protein transfer into a 
nitrocellulose membrane (Amersham Potran, Little Chalfont, United Kingdom), 
membranes were blocked in 10% non-fat milk (Bio-Rad) (dissolved in Tris- saline- buffer 
+0.5% of Tween20, TBSt) for 2 h. After the blocked membranes were rinsed quickly with 
TBSt to remove the excess of blocking solution and then incubated with the primary 
antibody at 4 °C overnight at the following dilutions: anti-BDNF (1:2500; Santa Cruz 
Biotechnology, CA, USA), anti-CB1 receptor (1:500, Thermo scientific, MA, USA), anti-
CB2 receptor (1:500, Thermo Scientific MA, USA), anti-GR receptor (1:500, Millipore, MA, 
USA), anti-PSD95 (1:1,000, Cell Signaling, Danvers, Massachusetts, USA), anti-
synaptophysin (1:500, Cell Signaling, Danvers, Massachusetts, USA), anti-
synaptotagmin (1:1,000, Cell Signaling, MA, USA), anti-BDNF (1:500; Santa Cruz 





anti-beta actin (1:20,000, Cell Signaling, MA, USA). After a washing step with TBS, 
membranes were incubated for two hours with donkey anti-mouse IgG (1:2,000; 
Amersham Potran, Little Chalfont, United Kingdom). The reactive bands were detected 
using an enhanced chemiluminescence reagent (ECLPrime®, Amersham, Little Chalfont, 
United Kingdom) and visualized using ChemiDoc Imaging Systems (GE ImageQuant 
LAS, MA- USA). Intensities of specific bands were quantified using Image Studio Lite (LI-
COR, Nebraska, USA) and normalized to anti-α-tubulin protein levels. Data were 
presented as % of the Veh group (control). 
 
BrdU and doublecortin (DCX) immunohistochemistry  
The sections containing the hippocampal formation received three washes in TBS. 
Subsequently, for the BrdU detection, the slices were incubated for 30 min in 2N HCl at 
37 °C for DNA denaturation. After this period, the slices were left for 5 min at 4 °C and 
washed three times with 0.1M boric acid (pH = 8.9), followed by three additional washes 
with TBS. For DCX detection, slices underwent an antigen retrieval step in citrate buffer 
(10mM Citric Acid, 0.05% Tween 20, pH 6.0) for 30 min at 70 °C. After that, slices were 
left on the bench for cooling down at room temperature. Slices were then incubated in a 
blocking solution (BSA 1% + 0.25% Triton 100X in TBS) for 2 h. Afterward, the slices 
were incubated overnight with the primary antibody rat anti-BrdU (1:100, Abcam, MA, 
USA) or goat anti-DCX (1:200, Santa Cruz Biotechnology, CA, USA) and subsequently 
incubated with the respective secondary antibodies for 1h (1:1,000, Alexa-Fluor anti-rat 
488, Invitrogen, Carlsbad, CA, USA,  or 1:1,000 Vectastin anti-goat biotinylated). In the 
case of DCX staining, we performed an additional step of incubation with A+B complex 
for one hour (1:1,000, ABC Elite-Vectastin kit, Vector Labs, Burlingame, CA, USA) 
followed by the color development using 3,3'-Diaminobenzidine (0.2mg/ml, 10 min, 
Sigma-Aldrich, Missouri, USA). For BrdU stained slices, we used Hoechst (Sigma-Aldrich, 
Missouri, USA) for total nuclei staining. At the end of the 
immunofluorescence/immunohistochemistry procedures, slices containing hippocampi 
were mounted on glass slides/coverslips with Cytoseal60 (BrdU, Electron Microscopy 
Science, Hatfield, PA, USA) or Permount (DCX-Fisher Scientific, Loughborough, United 






Microcopy, BrdU, and DCX analysis 
Six to eight slices containing dorsal parts of the hippocampus were analyzed for 
each experimental animal. BrdU+ and DCX+ cells were counted in a 40x objective by an 
experimenter blind to the treatment conditions. For BrdU quantification, a confocal 
microscopy (TCS-SPE, Leica, Wetzlar-Germany) was used. BrdU+ cells were counted in 
the subgranular zone (SGZ) of the dentate gyrus (DG) of the hippocampus. Z-stacks 
images obtained from 20 mm were projected as a 3D image (BrdU + Hoescht positive 
cells). A light microscope Olympus AX-70 (Olympus, Tokyo, Japan) was used to count 
DCX+ cells. A cell was considered positive for DCX only if the cell body was stained, and 
cells were located in the SGZ of the DG. DCX+ cells were also considered as migrating 
cells if they were in the granular zone of the DG. The total number of cells was normalized 
to the DG area determined with a 10× objective. The number of positive cells was 
estimated by calculating the total hippocampal volume, as determined by the sum of the 
areas of the sampled sections multiplied by the distances between them (Campos et al., 
2013). Total cells were expressed as the total amount of positive cells / mm3 of DG. 
 
Statistical analysis 
Data obtained were tested for normality (Kolmogorov-Smirnov's est), homogeneity 
of variance (Levene's test). Behavioral, ELISA and immunohistochemical data were 
analyzed by Student's t-test (Stress effects: Veh control vs. Veh stressed group) and two-
way ANOVA (treatment 1-AM251 or Veh; treatment 2- antidepressants or Veh within the 
stressed group) followed when appropriated, by the Duncan post-test. WB was analyzed 
by one-way ANOVA. Besides two-Away ANOVA, we also ran the Friedman non-
parametric test. The significance level was set at p < 0.05. Data were expressed as mean 
± SEM. Statistical analysis was performed by SPSS version 16.0 software (IBM, USA). 
 
Results 
Repeated treatment with AM251, a CB1 receptor antagonist/inverse agonist, did not 





Figure 2 (A-D) illustrates the effects of pre-treatment with AM251 in the behavioral 
effects of Esc in the TST and NSF. In the TST, chronic-stress induced increased 
immobility time when compared to the control-vehicle group (t(26) = 2.3, p < 0.05). Chronic 
treatment with Esc in stressed mice, decreased the immobility time in CUS-mice (F(1,47) = 
3.77,  p = 0.05). No effects of AM251(treatment 2) or the combination of ESC+ AM251 
were found (F(1,47) = 0.93,  p = 0.340). In the NSF (Figure 2C), stress increase the latency 
of feeding in the new environment (t(26) = 2.97, p < 0.01). Esc, with or without AM251 pre-
treatment, decreased chronic-stress induced increased latency to feed in a new 
environment (effect of treatment  2 - Veh or ESC- (F(1,50) = 15.90,  p < 0.001) without 
changing the parameters of feeding behavior in the home-cage. No effects of AM251 or 
the interaction between treatments were found (F(1,50) = 0.17,  p = 0.674).  No changes in 
the basal locomotor activity measured in the OF test were observed in any condition or 
treatment.  
 
Figure 2. Chronic CB1 receptor blockade attenuated the positive coping behavioral 
effects of escitalopram (Esc) in the tail suspension test (TST) but not in the novelty 





Latency to feed in a new environment in the NSF test, D- home cage food consumption 
in the NSF. Bars represent mean +/- SEM. *indicates the difference from the control 
group. #represents differences from the stressed-vehicle group. (N= 13-14/group). 
 
Figure 3 represents the results of the VFX and AM251 and their combination in the 
NFS and ST. In the NSF, stress was not able to increase the latency to feed  (t(5,95)= 1.44, 
p= 0.266). However, VFX was able to decrease the latency to feed in the new 
environment (treatment 2 F(1,25)= 4.2, p < 0,01). This effect was not antagonized by 
AM251 (Two-Way ANOVA; interaction treatment 1 vs treatment 2-F(1,25)= 9.7, p < 0. 001; 
Friedman test df= 2; 2= 49.5, p < 0.001).  In the ST, despite no changes in the total 
grooming behavior, CUS decreased the facial grooming behavior. Besides, VFX was able 
to prevent stress-induced decreased facial grooming behavior (F(1,25)= 4.7, p < 0.05). 
Although we observed a trend (F(1,25)= 3.36, p = 0.08), AM251 did not change facial 
grooming latency. No significant interaction effect between treatments were found (F(1,25)= 







Figure 3. Venlafaxine (VFX) prevents stress-induced anhedonia and anxiety-like 
behaviors. This effect was not attenuated by AM251. A-latency for the first episode of 
grooming in the Splash Test (ST), B- Facial grooming duration in the ST, C- Latency to 
feed in a new environment in the NSF test, D- home cage food consumption in the NSF. 
Bars represent mean +/- SEM. * indicates the difference from the control group. # 
represents differences from the stressed-vehicle group. (N = 7-8/group). 
 
Esc increased the expression of CB1 and decreases the expression of Glucocorticoid 
receptors in the hippocampus 
As illustrated in figure 4, repeated treatment with Esc in stressed animals increased 
CB1 expression in the hippocampus, an effect prevented by the pre-treatment with 
AM251 in stressed animals (F(3,14) = 19.7, p < 0.05). On the other hand, Esc, AM251, or 
their combination prevented the stress-induced increased expression of GR receptors in 






Figure 4. Escitalopram (Esc) facilitates CB1 but reduces GR expression in the 
hippocampus of chronically stressed mice. A – CB1, B – CB2, and C – GR levels in the 
hippocampus. Data represented as % of control (Ctrl - dot line). Bars represent mean +/- 






Pre-treatment with AM251 did not change the pro-proliferative effects of Esc in the 
dentate gyrus 
Stress did not significantly reduce cell proliferation in the DG (t(6)= 1.9, p = 0.09). 
However, Esc facilitated cell proliferation in the dentate gyrus (DG) of the hippocampus 
as demonstrated by the increase in BrdU positive cells in the figure 4 (treatment 2; F(1,12)= 
11.2, p < 0.01, figure 5).  AM251 did not antagonize the proliferative effect (treatment 1 
vs treatment 2; F(1,12) = 1.2, p = 0.3).  In the case of BDNF, no statistical differences 
between groups treated with Veh/Veh were observed (t(4.6)= 0.03, p = 0.9). Likewise, Esc 
and AM251 (treatment 1;F(1,13) = 0.2; treatment 2; F(1,13) = 0.5; p > 0.05) or their 
combination did not change BDNF levels in the hippocampus (treatment 1 vs treatment 
2; F(1,13) = 3.4, p = 0.08). However, CUS-Esc group seems to have increased levels of 
BDNF in the hippocampus when compared to the Veh/Veh non-stressed group (One-







Figure 5. Effects of stress and escitalopram (Esc) treatment in the A- BDNF levels in the 
hippocampus, and B- cell proliferation in the dentate gyrus (DG) of the hippocampus (H-
hilus; SGZ- subgranular zone; GL- granular layer). Bars represent mean +/- SEM. # 
indicates the difference from the stressed-vehicle group. (N = 3-5/ group). Magnification 
(20x. The bar represents 50m. 
 
In the dentate gyrus of chronically stressed mice, AM251 or VFX treatment did not affect 
the profile of the DCX+ cell 
Stress did not change the total number of DCX + cells (t (16) = 0.217, p = 0.83) nor 
the percentage of migrating DCX+ cells in the granular layer (t (17) = 0.355, p = 0.72), as 
observed in the figure 6. The two-way ANOVA did not reveal any effect on the number of 
DCX + cells present in the dentate gyrus of any treatment alone: AM251 (F(1.11) = 0.154, 
p > 0.05) and VFX (F(1.11) = 2.635, p > 0.05), or any interaction between treatments (F 
(1.11) = 0.575, p > 0.05). Likewise, regarding percentage of DCX+ migrating cells, there 
was no differences between any of the treatment-independent groups: AM251 (F(1.11) = 
1.362, p > 0.05) and VFX (F(1.11) = 0.051, p > 0.05) or the interaction between 







Figure 6. Effects of stress and venlafaxine (VFX) treatment in the A- The migrating 
process of doublecortin (DCX) positive cells in the granule cell layer of the hippocampus, 
and B- Total DCX cells in the dentate gyrus of the hippocampus. Bars represent mean 
+/- SEM. (N = 3-5/ group). Magnification (20x) bar represents- 50m. 
 
The CB1 receptor is involved in the effects of Esc in facilitating the expression of PSD-
95, but not presynaptic proteins, in the hippocampus 
In figure 7C, we observe a trend in Esc increases the expression of PSD-95 
(F(3,14)=2.1, p = 0.06; One-way ANOVA) in the hippocampus, an effect attenuated by 
AM251.  On the other hand, in the case of the synaptic protein synaptophysin, Esc 
facilitates its expression. However, the pre-treatment with AM251 did not influence this 
effect (F(3,14)=11.5, p < 0.05, Figure 7B). No differences in the expression of 






Figure 7. Effects of chronic stress and the treatment with escitalopram (Esc), or AM251 
in the expression of pre and postsynaptic proteins. A – Synaptotagmin, B – 
Synaptophysin, and C – PSD-95 levels in the hippocampus. Data represented as % of 
control (Ctrl - dot line). Bars represent mean +/- SEM. * indicates the difference from the 
AM251 + Veh and AM251 + Esc groups. (N = 3-5/ group).  
 
Discussion 
The results of the current study indicated that repeated Esc and VFX treatment 
decreased anxiety and despair-like behaviors that were induced by stress. Moreover, our 





expression of cannabinoid CB1 receptor, GR, synaptophysin and PSD95 in the 
hippocampus. In order to investigate whether the anxiolytic and antidepressant-like 
behaviors induced by Esc and VFX are modulated by cannabinoid system, we tested 
mice submitted to CUS paradigm and treated with cannabinoid CB1 inverse agonist, 
AM251, following antidepressant administration. Firstly, we conducted one experiment to 
evaluate the involvement of CB1 receptor in the long-term effects of Esc. Our results in 
this experimental design indicated that the decrease in passive coping strategies of Esc 
was attenuated by the pre-treatment with AM251 in the TST. In a different way, the 
anxiolytic effect in the NSF was not affected by co-administration of AM251. After that, 
we conducted another experiment to evaluate the long-term effect of the co-
administration of AM251 and VFX. In the ST test our results indicated that the 
antidepressant-like effect of VFX was not influenced by pre-treatment with AM251. In the 
same way of Esc, when the animals were submitted to NSF, the effects of VLX were 
sustained with co-administration of AM251.  
Our behavioral results indicate that the CB1 receptor is involved in the anti-stress 
effects of Esc, an SSRI, but not, VFX, an SSNRI. Several studies have suggested that 
the CB1 receptor and other components of the endocannabinoid system seem to be up-
regulated after chronic treatment with AD in mice submitted to homotypic stress (Hill et 
al., 2006a, 2006b; 2008; 2009). Conversely, Poleszak et al. (2019), have demonstrated 
that acute administration of AM251 potentiated the antidepressant-like effect of Esc in 
rats submitted to the forced swimming test.  Herein, we observed an attenuation of 
antidepressant-like effect in the TST with repeated Esc and AM251 treatment under 
stress conditions. This fact could be related to the cross-talk mechanisms between brain 
CB1 receptor and serotoninergic systems.  
The 5-HT1A receptor is the serotonergic receptor more likely to be directly linked 
with the antidepressant effects of SSRIs (Celada et al., 2004). Preclinical studies have 
shown an increase of 5-HT1A receptor-mediated hippocampal transmission after long-
term treatment with SSRIs and other antidepressant drug classes (Haddjeri et al., 1998). 
A notable finding in a study performed by Mato et al. (2007) showed that CB1 receptors' 
deletion reduced the hypothermic response induced by the 5‐HT1A agonist 8-hydroxy-2-





the CB1 receptor might alter the expression and functionality of 5‐HT1A receptors. In the 
same way, our proposal in this study is that chronic inactivation of the CB1 receptor alters 
the functionality of the 5-HT1A receptor and, in consequence, affects the antidepressant 
activity of Esc.  
Regarding VFX, our results suggest that the antidepressant-like effect of VFX 
occurs in an independent fashion of CB1 activation. Beyond antidepressant-like effect 
elicited via serotonergic neurotransmissions, VFX promotes its effects by modulating 
noradrenergic and even dopaminergic receptors in a sequential manner (Muth et al., 
1991; Andrews et al., 1996; Harvey et al., 2000). Besides, VFX potentiates 
electrophysiological activity in noradrenergic neurons of the locus coeruleus (Haskins et 
al., 1985), a mechanism that can be relevant for its antidepressant effects. Thus, VFX 
extensive modulation on monoaminergic pathways could explain the absence of 
interacting effects between VFX and AM251.  
Chronic stress is associated with a down-regulation of CB1 receptor signaling (Hill 
& Gorzalka, 2005; Hill et al., 2008b; Reich et al., 2009; Hu et al., 2011; Lee & Hill, 2013). 
Our results suggested that the repeated administration of Esc facilitates the expression 
of CB1 receptors in the hippocampus. This agrees with the study by Smaga et al. (2017), 
showing that Esc chronic treatment increased the expression of CB1 receptor in the same 
structure in rats. However, the mechanisms by which antidepressants regulate the CB1 
receptor expression are still unclear. It has been suggested that tricyclic antidepressants, 
such as desipramine, may also increase the intracellular transport and expression of CB1 
receptors in the cell membrane, enhancing the functional activity of CB1 receptors (Hill et 
al., 2006c). Therefore, we hypothesize that AM251 affecting the intracellular transport of 
CB1 receptors in the cell membrane could prevent some of the effects of Esc evaluated 
in the present study.  
We also observed that the CB1 receptor impacted the pro-proliferative effects of 
Esc in the DG using the thymidine analog BrdU. Regulation of adult hippocampal 
neurogenesis occurs at different stages, including cell proliferation, differentiation, and 
survival. Among the regulatory factors of neurogenesis, stress has been identified as a 
potential inhibitor of dentate cell proliferation (Gould et al., 1998; Czéh et al., 2001; 





to the administration of different classes of antidepressants, and it may contribute to the 
anti-stress effect of these drugs (Malberg et al., 2000; Malberg & Duman, 2000). In 
agreement, facilitation of endocannabinoid signaling induces the pro-proliferative effects 
of neural progenitor cells (Jin et al., 2004; Aguado et al., 2005, Campos et al., 2013). On 
the other hand, genetic deletion of CB1 receptors in mice leads to a 50%  reduction in the 
BrdU positive cells in the hippocampus, suggesting that the activation of CB1 receptors 
in the neurogenic niche is an important regulator of adult neurogenesis (Jin et al. 2004). 
Therefore, the diminished proliferation in the DG found in our study agrees with previous 
findings showing that impaired CB1 signaling negatively impacts the neurogenic niche.  
Corticoids play a crucial regulatory role in progenitor cell proliferation in neurogenic 
niches. Manipulation of circulating corticoids leading to enhanced glucocorticoid signaling 
dampens proliferation of progenitor cells in the DG (Gould et al., 1992; Cameron & Gould, 
1994). Otherwise, after adrenalectomy, for example, the absence of circling corticoids 
prompts this process (Gould et al., 1992; Cameron & Gould, 1994). The specific 
mechanisms by which glucocorticoid hormones modulate such regulation are not entirely 
understood. The mineralocorticoid (MR) and glucocorticoid (GR) receptors are 
abundantly expressed in the hippocampus (De Kloet et al., 1987; Herman et al., 1993). 
Several lines of evidence indicate an interplay between glucocorticoids and the 
endocannabinoid system to control the negative feedback regulation of the hypothalamic-
pituitary-adrenal (HPA) axis and regulation of adaptive responses of coping stress (Hillard 
et al., 2016). Glucocorticoid activation, induced by stressful situations or treatment with 
corticosterone, evokes endocannabinoid-mediated suppression of neurotransmission in 
the hippocampus (Wang et al., 2012). Likewise, the cross-talk between both systems 
appears not to be exclusive of the hippocampus. The activation of CB1 receptors in the 
PFC facilitates HPA axis negative feedback, for instance (Hill et al., 2011; Wang et al., 
2012). Thus, the mechanism by which CB1 antagonism attenuated the increase of cell 
proliferation induced by Esc might be related to the modulation of corticoid signaling. In 
parallel with enhanced proliferation in DG, our results also demonstrated that chronic 
treatment with Esc decreases the expression of GR in the hippocampus, an effect 
attenuated by the association with AM251. These results suggest that the antidepressant, 





Concerning neuroplastic effects of repeated treatment with ADs, we also evaluated 
the cell population positively labeled with doublecortin (DCX+), a microtubule protein 
closely associated with the immature neuronal phenotype (Couillard-Despres et al., 
2005). We found no differences regarding the total number of DCX+ cells or the 
percentage of migrating DCX+ cells in chronically stressed mice treated with VFX, 
although the literature report stress as a negative modulator of DCX+ expression (Oomen 
et al.; 2007; Fogaça et al.; 2018). However, except for their migratory ability, data 
addressing the exact role of DCX+ cells during neurogenic events are scarce. In this 
sense, Kempermann and collaborators indicated that DCX+ cells may be responsible for 
a complex modulation of the microenvironment in neurogenic niches, mediating 
connectivity between different regions of the DG (Kempermann et al., 2015). The amount 
of DCX+ cells is not necessarily related to ADs behavioral effects. Instead, the 
microenvironment modulation promoted by DCX+ could be more relevant to the ADs 
effects than its absolute number (Wang et al., 2008). However, it is relevant to mention 
that Wang et al. (2008) showed that fluoxetine is able to restore the dendritic arborization 
of DCX+ cells observed in chronically stressed-mice without changing the total number 
of these cells. Although we have observed no effect on DCX+ cells in our study, their 
participation in the anxiolytic- and antidepressant-like effects observed cannot be ruled 
out without new experiments aiming to test this hypothesis.   
Neuroplastic changes are proposed as a critical factor of AD mechanisms at 
cellular and molecular levels. Changes in the number of newly generated cells at different 
neurogenesis could work as a refined mechanism of neuronal circuitry modulation, 
modifying the microenvironment and modulating synaptic communication. Synaptophysin 
and postsynaptic density protein 95 (PSD‐95) have been implicated in mechanisms of 
activity‐dependent neuroplasticity underlying different psychiatric disorders (Eastwood et 
al. 1995; Honer et al. 1999; Coley & Gao, 2018). PSD-95 is an essential scaffolding 
protein of the postsynaptic density at excitatory synapses (Lin et al., 2006), while 
synaptophysin is a marker of pre-synapse development and activity (Wiedenmann & 
Franke, 1985). The expression of synaptophysin and PSD-95 markedly decreases in the 
hippocampus after stress exposure (Thome et al., 2001; Li et al., 2015; Qiao et al., 2017). 





basal synaptic function. These findings corroborate those described by Li et al. (2015), 
showing that the expression of both proteins in the hippocampus increased after 
treatment with Esc in stressed rats. 
AM251 attenuated PSD-95 expression in the hippocampus of stressed rats. PSD-
95 protein plays a crucial role in the retrograde synaptic signaling elicited by the CB1 
receptor to regulate the activity-dependent inhibition of synaptic strength in the brain (Kim 
et al., 2008; Chen et al., 2011). Thus, It is possible, then, that AM251 is interfering with 
the behavioral effects of Esc by preventing the increase in PSD-95. 
In summary, the present study shows that the CB1 receptor blockade influenced 
the antidepressant-, but not the anxiolytic-like effect of Esc. This blockade, however, did 
not modify the effects of VFX, an SRNI. CB1 receptor antagonism also interfered in 
hippocampal proliferation rate and synaptic markers. Our results bring new pieces of 
evidence for understanding the role of CB1 receptors in the anti-stress effect of 
antidepressants.   
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In the present work it was demonstrated that selective activation of the 
postsynaptic 5-HT1A receptor by NLX-101 resulted in functional recovery and enhanced 
neuroplasticity in mice with cerebral ischemia (Chapter 3). Specifically, NLX-101 
impacted positively dendritic remodeling and prevented the decrease of brain-derived 
neurotrophic factor (BDNF) levels in the prefrontal cortex (PFC) and hippocampus. NLX-
101 also affected synaptic plasticity proteins, increasing the expression of postsynaptic 
density protein 95 (PSD-95) and synaptophysin (SYN) protein levels in the hippocampus 
of ischemic mice. Besides this, it was tested the hypothesis that activation of the 
postsynaptic 5-HT1A receptor by NLX-101 could result in an increase of spatial object 
pattern separation (OPS) performance in aged rats (Chapter 4). In this study it was 
demonstrated that acute or repeated treatment with NLX-101 resulted in a significant 
cognitive improvement of aged rats in the OPS task. This effect was accompanied by an 
increase in hippocampal neurogenesis as well as in BDNF and PSD-95 protein levels in 
the hippocampus of those animals. 
It was addressed in this thesis whether the selective activation of the 5-HT1A 
receptor using the biased agonist NLX-101, could result in functional recovery and an 
increase in neuroplasticity in two different conditions (cerebral ischemia and aging). This 
hypothesis was developed based on preclinical studies that demonstrated that non-
biased agonists promote significant positive effects on the consequences of cerebral 
ischemia, although clinical studies with repinotan (a full agonists) have not shown any 
benefits (see chapter 2). The problem behind this issue is that classic agonists 
indiscriminately activate both auto-receptors, which exert an inhibitory effect on 
serotonergic tone, and heteroreceptors in projecting areas that presents positive effect 
on neuroprotection. In contrast biased agonists that preferentially activate either raphe-
located 5-HT1A autoreceptor or post-synaptic heteroreceptor may yield a more 
favourable therapeutic profile accompanied by lower incidence of side effects, compared 
with non-biased agonists. The preferential targeting by biased agonists of raphe-located 
5-HT1A autoreceptors or post-synaptic heteroreceptors is not due to differences in the 
receptor protein itself. The distinct responses to 5-HT1A biased agonists are probably 
attributable to regional coupling differences of the 5-HT1A receptors to certain G-protein 





Tancredi, 2011). This conformity results in similar receptors which only differ with regard 
to coupled G proteins, hence the difference in responses of F13714 and F15599 upon 
the receptors are purely related to the effect that the compounds generate upon the 
receptors and not on the binding affinity per se. Different studies have demonstrated 
that F15599 preferentially activates post-synaptic 5-HT1A heteroreceptors over raphe-
located autoreceptors (Newman-Tancredi et al., 2009; Assié et al., 2010; 
Depoortère et al., 2010). F13714 exerts an opposite pharmacological profile with more 
pronounced activity at raphe-located autoreceptors, and only modest activation at post-
synaptic heteroreceptors (Assié et al., 2006; Newman-Tancredi, 2011). 
Experimental evidence shows that 5-HT1A receptors participate in the regulation of 
neuroplastic processes in the adult brain. This include neurochemical responses that alter 
synaptic function (increase or decrease in the number of receptors, changes in the 
synthesis or release of neurotransmitters or changes in synaptic stability), synaptic 
strength, synaptogenesis, neurogenesis, gliogenesis and changes in dendritic 
morphology (size and number of dendritic tree branches, variation in density and 
morphology of dendritic spines) (Bruel-Jungerman et al., 2007; Gulyaeva, 2017; Dan, 
2019). Linked to this, 5-HT1A receptors have been involved in the modulation of long-term 
potentiation (LTP), a phenomenon characterized by the persistent increase in synaptic 
strength after high-frequency stimulation that has been related to learning and memory 
function (Bliss and Collingridge, 1993).  
The hippocampus and PFC play a central role in spatial learning, memory and 
emotional control, which has been closely related to the plasticity of dendritic arborization 
and morphological changes (Knafo et al., 2004; Frankfurt and Luine, 2015; Milner and 
Klein, 2016). Brain ischemia has a profound effect on the structure and function of 
synapses that is associated with impairments in neurological functions such as cognitive 
and emotional impairments (Hasbani et al., 2000; He et al., 2012). Accordingly, in Chapter 
3 it was demonstrated that cerebral ischemia negatively impacted dendritic remodeling in 
the hippocampus and PFC of mice. This finding could be related to the cognitive and 
emotional deficits observed in those animals. In this perspective, repeated administration 
of NLX-101 impacted positively dendritic remodeling in the hippocampus and PFC of 





These data are in agreement with other studies demonstrating that agonists of the 5-HT1A 
receptor stimulates dendritic remodeling in the hippocampus and in cortical regions. Yan 
et al. (1997) have demonstrated a reduction in the dendritic length and density of dendritic 
spines of the granular neurons of the hippocampus in rats in the early postnatal period 
with absence of 5-HT. These effects were prevented by the administration of the 5-HT1A 
receptor agonist buspirone. Also 8-OH-DPAT promoted an increase in the number and 
length of dendrites in neuro 2A cells transfected with 5-HT1A receptors and SK-N-SH cells 
endogenously expressing this receptor (Fricker et al., 2005). In addition, the involvement 
of the 5-HT1A receptor in dendritic morphology has also been demonstrated in culture of 
neurons extracted from the hippocampus or cortex of rat embryos. Rojas et al, (2014) 
showed growth of secondary dendrites in hippocampal neurons stimulated by 5-HT, an 
effect blocked by the antagonist WAY-100635, while Yoshida et al (2011) demonstrated 
effects on the density of dendritic spines of cortical neuron culture when treated with 8-
OH-DPAT. 
However, the specific molecular mechanisms by which the 5-HT1A receptor 
impacts neuronal morphology in the adult brain are not fully elucidated yet. Evidence 
indicates that the increase in the density of dendritic spines and the formation of new 
synapses occurs through the sequential activation of the ERK 1/2 and PKC pathways 
(Mogha et al., 2012; Rojas et al., 2016). Of note, NLX-101 has functional selectivity for 
ERK1/2 activation in vulnerable brain regions expressing postsynaptic 5-HT1A 
heteroreceptors (Newman-Tancredi, 2009). 
 Also a decrease was observed in BDNF levels and the expression of SYN and 
PSD-95 in the PFC and hippocampus in the mice submitted to brain ischemia, an effect 
reversed by treatment with NLX-101. BDNF is a neurotrophic factor that plays an 
important role in regulating the survival of neurons, neurogenesis, and neuroplasticity 
(Begni et al., 2017). Favorable effects of BDNF on functional recovery and neuroplasticity 
after brain ischemia have been reported (Schäbitz et al., 2007; Espinera et al., 2013; 
Soares et al., 2016). All these results suggest that the effect of NLX-101 on BDNF levels 
may be associated with neuroprotective effects after ischemic insult. Moreover, both SYN 
and PSD-95 are the main proteins that participate in structural synaptic plasticity (Sadigh-





hippocampus after experimental brain ischemia, and the recovery in the levels of these 
proteins in the hippocampus may determine the degree of functional recovery after an 
ischemic insult. In summary, the protective effects of NLX-101 on cortical and 
hippocampal neurons paralleled with their restorative or stimulating effect on the 
expression of BDNF, SYN and PSD-95, suggesting a relationship between these 
proteins, dendritic remodeling, and functional recovery after cerebral ischemia. 
The hypothesis tested in this work (chapter 3) was based on preclinical studies 
that demonstrated that non-biased 5-HT1A receptor agonists exerted neuroprotective 
effects in animals with cerebral ischemia (see chapter 2, table 2). However, the only 
clinical study with repinotan (a full 5-HT1A receptor agonist) did not show any therapeutic 
benefits in patients with stroke (Teal et al., 2009). The cellular mechanism by which 5-
HT1A receptor agonists produce neuroprotection need more clarification and systematic 
studies. Only two studies confirmed direct 5-HT1A receptor involvement by showing that 
the neuroprotective effect of 5-HT1A receptor agonist was blocked by 5-HT1A receptor 
antagonist, WAY100635 (Shaper et al., 2000; Mishima et al., 2005). The problem behind 
this issue is that classic 5HT1A receptor agonists indiscriminately activate both 
autoreceptors, which exert an inhibitory effect on serotonergic tone, and heteroreceptors 
located in projecting areas. In contrast, the biased 5-HT1A receptor agonists that 
preferentially activate either raphe-located 5-HT1A autoreceptor or post-synaptic 
heteroreceptor might yield a more favorable therapeutic profile accompanied by a lower 
incidence of side effects, compared with the 5-HT1A receptor non-biased agonists. 
Although the results described herein suggested positive effects for NLX-101, it remains 
to be investigated whether the biased 5-HT1A receptor agonism underlies the NLX-101 
effects in cerebral ischemia conditions. Depending on the concentration, NLX-101 can 
also act as a conventional 5-HT1A receptor agonist acting at both pre- and postsynaptic 
receptors. Besides, the window between biased and non-biased 5-HT1A receptor activity 
can be small as 2-4 fold (Van Goethen et al., 2015). 
Aging is another condition addressed in this thesis in which neuroplasticity is 
reduced. In addition, neurodegeneration and impaired hippocampal neurogenesis are 
age-related processes particularly related to the cognitive decline observed in elderly 





separation is a cognitive process that allows the formation of distinct representations out 
of similar inputs. There is evidence for a connection between adult neurogenesis and 
pattern separation (Clelland et al., 2009; Creer et al., 2010; Chen et al., 2012). The 
dentate gyrus (DG) of the hippocampus is one area of the brain where ongoing adult 
neurogenesis occurs (Zhao et al., 2008). One of the suggested roles for the adult 
neurogenesis of adult mammals is to assist the pattern separator in the DG, reducing the 
interference with old information (Clelland et al., 2009). If neurogenesis is down-regulated 
by aging, new information will be stored in overlapping cell groups and therefore 
memories can interfere with each other, leading to impaired pattern separation. Thus, 
pharmacological interventions that increase hippocampal neurogenesis targeting 5-HT1A 
might represent an interesting strategy to improve pattern separation performance in old 
individuals. 
Several studies evaluated the increase in hippocampal neurogenesis by activation 
of 5-HT1A receptor using different agonists. Santarelli et al. (2003), demonstrated that the 
therapeutic effects of antidepressants occurred due to a stimulus of hippocampal 
neurogenesis involving direct participation of 5-HT1A receptors. Knockout mice for 5-HT1A 
receptors showed a significant decrease in hippocampal neurogenesis and were unable 
to respond to chronic treatment with the antidepressant fluoxetine, a serotonin selective 
reuptake inhibitor (SSRI) (Santarelli et al., 2003). Accordingly, activation of the 5-HT1A 
receptor by 8-OH-DPAT, resulted in increased levels of neural progenitor cells in the DG 
of the hippocampus, an effect blocked by the 5-HT1A antagonist WAY-100635 (Banasr et 
al., 2004; Klempin et al., 2010; Soumier et al., 2010) or by the ERK 1/2 signaling inhibitor, 
U0126 (Cai et al., 2019). Chronic treatment of rats with tandospirone, a partial 5-HT1A 
receptor agonist, also resulted in increased cell proliferation and neurogenesis (Rao and 
Shetty, 2014; Murata et al., 2015). 
In the present thesis it was demonstrated that acute and repeated NLX-101 
treatment reversed the effects of aging in the OPS task (Chapter 4). These results extend 
previous findings wherein NLX-101 has been shown to present beneficial effects in a 
pattern separation task (Van Goethem et al., 2015) and to alleviate the detrimental effects 
of phencyclidine (PCP) on memory in rats in the hole-board test (Depoortère et al., 2010). 





in the OPS task was investigated. In accordance with previous studies, aged animals 
presented a reduction in the hippocampus of SYN, PSD-95 protein levels as well as 
neurogenesis, which were implicated in the learning and memory deficits (van Guilder et 
al., 2011). Because NLX-101 increased the BNDF protein levels, PSD-95 expression and 
neurogenesis in the hippocampus, it can be argued that NLX-101 acted on increasing 
pattern separation performance by improving neuroplasticity in the hippocampus of aged 
rats. 
The results presented in this thesis demonstrate the relevance of the 5-HT1A 
receptor as a pharmacological target for the treatment of different neuropsychiatric 
conditions. In the described studies, it is particularly evident that the activation of the 
postsynaptic receptor by the biased receptor agonist NLX-101, has a positive effect on 
specific neuroplastic processes that are related to functional recovery in aged rodents or 
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The present thesis aimed to demonstrate the involvement of 5-HT1A receptors in 
different experimental conditions including cerebral ischemia and aging. It was 
hypothesized that selective activation of 5-HT1A post-synaptic receptors by NLX-101, a 
‘biased’ 5-HT1A receptor agonist, would increase neuroplasticity and promote functional 
recovery. 
Chapter 1 represented the general introduction and aim for the research described 
in the thesis. 
In chapter 2, the currently available data on the effects of 5-HT1A agonists in 
experimental models of cerebral ischemia was summarized. The studies described in this 
review provide a clear demonstration that detrimental parameters associated with 
cerebral ischemia can be attenuated via activation of 5-HT1A receptors. Such studies 
support the rationale for pursuing an investigation of this class of compounds and suggest 
that they could lead to promising pharmacotherapeutics for cerebral ischemic diseases. 
In chapter 3 an experimental study using NLX-101 and the selective serotonin 
reuptake inhibitor (SSRI) Escitalopram (Esc) in mice with bilateral common carotid 
oclusion (BCCAO) was presented. NLX-101 attenuated cognitive impairments and 
despair-like behaviors in BCCAO mice. Moreover, NLX-101 blocked the increase in 
plasma corticosterone levels and restored hippocampal protein levels of plasticity 
markers including brain-derived neurotrophic factor (BDNF), synaptophysin (SYN), and 
postsynaptic density protein-95 (PSD-95). This compound also impacted positively 
dendritic remodeling in the hippocampus and PFC of ischemic mice. The results suggest 
that biased 5-HT1A post-synaptic receptor agonists might constitute promising 
therapeutics for the treatment of functional deficits after brain ischemia.  
 Experimental and clinical evidence suggests that pattern separation linearly 
declines with increasing age. In chapter 4 the effects of acute and repeated treatment 
with NLX-101 on spatial object pattern separation (OPS) performance in aged rats were 
described. Aged rats were incapable to discriminate any new position of the objects in 
the arena, reflecting the detrimental effects of aging on OPS performance. However, 
when aged animals were treated acutely or repeatedly with NLX-101 they showed a 
significant cognitive improvement in the OPS task. This effect was accompanied by an 





NLX-101 also stimulated neurogenesis (DCX-positive neurons) in the DG of the 
hippocampus of aged rats. These findings support a rationale for targeting cortical 5-HT1A 
post-synaptic receptors as a strategy for treating cognitive impairments related to aging. 
Chapter 5 presents the impact of CB1 receptor blockade on the behavioral and 
neuroplasticity effects of the SSRI Esc and the serotonin–norepinephrine reuptake 
inhibitors (SNSRI) velanfaxine (VFX) in mice submitted to the chronic unpredictable 
stress (CUS) paradigm. Chronic blockade of the CB1 receptor by the CB1 receptor 
antagonist AM251 attenuated the antidepressant-like effects of Esc, but not its anxiolytic-
like effects. AM251, however, failed to change the antidepressant- and anxiolytic-like 
effects of VFX. On the other hand, AM251 attenuated the pro-proliferative effects of Esc 
in the dentate gyrus of the hippocampus. Moreover, Esc increased the expression of the 
CB1 receptor and PSD-95 in the hippocampus, an effect attenuated by AM251. These 
results suggest that antidepressants, in particular SSRIs, might exert their behavioral 
effects with a minor participation of CB1 receptors.  
Taken together, the findings of the present thesis demonstrate that 5-HT1A post- 
synaptic receptors could represent a promising pharmacological target to treat the 




















Cerebral ischemia is one of the principal causes of death and disability worldwide 
according to the World Health Organization and represents an increased economic 
burden due to treatment and post-ischemia care. In Europe, more than one million of new 
cases occur each year, and currently six million of survivors are estimated to be alive. In 
27 European Union (EU) countries, the annual costs for brain ischemia treatment and 
care are estimated to be 27 billion euros, with 18.5 billion accounting for direct medical 
costs and 8.5 billion for indirect costs with loss of productivity for example. In the USA, a 
total of $65.5 billion was spent on brain ischemia care in 2008. The American Heart 
Association and The American Stroke Association projected for the years 2012 to 2030, 
that the total direct medical cost for brain ischemia will triple and reach up to $184.1 billion. 
Costs related to brain ischemia care in Brazil are also considerable, with an aggregate 
national health care expenditures for the acute treatment of brain ischemia of $449.3 
million in 2006-2007. In face of the high costs and the economic impact behind this 
disease, the problem lies in the fact that advances in pharmacotherapy for cerebral 
ischemia have been limited. Therefore, the research and development of new drugs is 
imperative. 
Global cerebral ischemia occurs commonly in patients who have a variety of 
clinical conditions including cardiac arrest, shock, asphyxia and in patients undergoing 
complex cardiac surgery. The commonest postulated mechanism for ischemic brain injury 
after cardiac arrest is global cerebral ischemia from systemic hypoperfusion affecting the 
whole brain. Irrespective of the etiology of cerebral ischemia, cellular and molecular 
processes trigger a cascade of events that culminate in a final common pathway, resulting 
in ischemic neuronal injury. Identification of these injury mediators and pathways in a 
variety of experimental animal models of global cerebral ischemia, such as bilateral 
common carotid artery occlusion as used in this thesis, has led to the investigation of 
target-specific neuroprotective strategies that are critical to clinical brain injury outcome. 
Usually a patient who survives from cerebral ischemia, as also observed in 
rodents, may develop a vast number of neurological and neuropsychiatric disorders, 
including cognitive and/or affective dysfunctions. These impairments impact directly the  





detrimental consequences of brain ischemia is relevant not only from a medical 
perspective but also from a socioeconomic standpoint. 
Many different pharmacological strategies have been considered for the treatment 
of cerebral ischemia. In this context, some preclinical studies supported the idea that 
activation of the 5-HT1A receptor with conventional agonists of this receptor, could have 
benefical effect on the consequences of cerebral ischemia in different animal models. 
Although these receptor agonists have shown interesting results in these preclinical 
studies, disappointed results were observed in clinical trials. The reason for this could be 
related to poor selectivity resulting in partial agonist, i.e. weak, activity on 5-HT1A 
receptors. Moreover, these receptor agonists activate indiscriminately both 5-HT1A 
presynaptic autoreceptors and postsynaptic heteroreceptors, and this lack in receptor 
discrimination of 5-HT1A agonists may result in divergent or even opposite effects.  
 Interstingly, a new generation of so-calles biased receptor agonists has become 
available that discriminate between receptor subpopulations in specific brain regions. 
NLX-101, a biased postsynaptic 5-HT1A receptor agonist, has been extensively tested in 
preclinical studies and presents interesting antidepressant and pro-cognitive effects that 
could contribute to the treatment of the functional impairments after cerebral ischemia. In 
this thesis, for the first time to my knowledge, the effects of the biased 5-HT1A receptor 
agonist NLX-101 was evaluated in a mouse bilateral common carotid artery occlusion 
(BCCAO) model of brain ischemia. It was demonstrated that the functional deficits of 
these mice can be restored by selective 5-HT1A post-synaptic activation. 
In summary, it was shown that: 
- NLX-101 attenuated cognitive impairments induced by BCCAO in mice. 
- NLX-101 improved passive coping strategies of BCCAO mice in the forced 
swimming test. 
- NLX-101 decreased basal plasma corticosterone levels in BCCAO mice. 
- NLX-101 affected BDNF protein levels in the prefrontal cortex (PFC) and 
hippocampus of BCCAO mice.  
- NLX-101 impacted dendritic remodeling in the PFC and hippocampus of 





- NLX-101 decreased neurodegeneration and increased synaptic plasticity 
markers in BCCAO animals.      
Thus, direct targeting of a 5-HT1A receptor subpopulation with biased agonists 
such as NLX-101 might constitute a new strategy for therapeutic intervention in brain 
ischemia patients. 
Another topic addressed in this thesis is related to the cognitive decline caused by 
aging. Themes related to aging have been increasingly studied due to the increase in the 
elderly population in the world. The number of older persons (over 65 years old) that is 
an age above X years, is expected to double again by 2050, when it is projected to reach 
nearly 2.1 billion.  An aging global population will have a serious impact on the world’s 
economies to the point of hampering growth and changing public policy. Nations will be 
forced to improve their healthcare systems so they are more effective and efficient in 
order to provide better treatment for the elderly at a lower cost. 
It is vital to understand how age impacts cognition and which preventative or 
treatment strategies might preserve cognition into advanced age. Pharmacological 
intervention aimed at enhancing or maintaining cognitive functions has been the focus of 
intensive research in the recent years. In this context, 5-HT1A receptors have been shown 
to be involved in important aspects of cognitive function including attention, learning and 
memory, and neuroplasticity processes. Of note, acute administration of the biased 5-
HT1A receptor agonist NLX-101 has been shown to improve performance of healthy adult 
rats in the object pattern separation (OPS) task. In this thesis, it was demonstrated that 
aged rats presented a cognitive deficit in the OPS task, reflecting the detrimental effect 
of aging on pattern separation performance. Moreover, when these aged animals were 
treated acutely or repeatedly with NLX-101 they showed a cognitive improvement in the 
OPS task, and this effect was accompanied by an increase in neuroplasticity. These 
findings support the rationale for targeting post-synaptic cortical 5-HT1A receptors as a 
treatment for cognitive deficits related to aging.  
Clearly, the results from these studies provided new insights regarding the 
contribution of the 5-HT1A receptor in improving plasticity and functional recovery in 
different neurological conditions. Specifically, the use of a new class of drugs known as 





system could represent a promising strategy to treat cerebral ischemia diseases and 
cognitive decline due to aging. However, this issue needs to be investigated in future 
studies. More scientific evidence is needed to address whether biased 5-HT1A agonism 
underlied the NLX-101 positive effects in cerebral ischemia and pattern separation in 
aged rats. Depending on the concentration, NLX can act as a conventional agonist at 
both pre-and postsynaptic receptors and, the range between biased and non-biased 5-
HT1A receptor agonism can be narrow. Thus, the present results could open up a new 
world of possibilities to be explored in the treatment of functional deficits impacting daily 
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